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1 
INTRODUCTION 
Myeloperoxidase (MPO), an enzyme of the heme peroxidase 
superfamily in mammals is present within the azurophilic granules of 
leukocytes. It plays a major role in innate host defence by participating in 
the oxygen dependent killing of invading pathogens. MPO exhibits its 
anti-microbicidal property by catalyzing a unique reaction in which 
hydrogen peroxide reacts with chloride ions. The product formed by this 
reaction is the potent oxidant hypochlorous acid 1. In addition, evidence 
shows that increased enzymatic activity of MPO is seen in many chronic 
inflammatory conditions. MPO is capable of generating reactive oxygen 
species that modify lipids and proteins which contributes to 
atherogenesis. Recent studies have shown that low density lipoprotein 
(LDL) on exposure to reactive nitrogen and halogen species by MPO gets 
converted into more atherogenic forms in the walls of the blood vessel 2. 
Also MPO participates in the generation of dysfunctional high density 
lipoprotein (HDL) contributing to pro-inflammatory state which triggers 
atherosclerosis 3. Apart from this, MPO consumes endothelial derived 
nitric oxide, thus reducing its bioavailability and impairing its functions 
such as vasodilatation and anti-inflammatory properties. Thus MPO is 
found to contribute to endothelial dysfunction, the major pathogenetic  
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mechanism in the process of atherosclerosis. Plasma MPO concentrations 
have been found to provide independent prognostic value to predict 
adverse outcomes in patient population with coronary artery disease 2. 
Diabetes mellitus (DM) is a metabolic disorder, which occupies the 
seventh leading cause of death 4. The burden caused by the morbidity and 
mortality in patients with type-2 DM is mainly driven by its vascular 
manifestations. The underlying pathology of vascular complications is 
centrally linked to amplified production of reactive oxygen species, 
specifically superoxide radicals and hydrogen peroxide (H2O2). 
Superoxide radicals generated from the uncoupling of electron transport 
chain is found to oxidize endothelial derived nitric oxide and thus lead to 
endothelial dysfunction. H2O2 derived from superoxide is the principal 
substrate for leukocyte peroxidases, in particular MPO. DM is associated 
with increased risk of premature vascular disease due to accelerated 
atherosclerosis. Inflammatory reactions take place in early phase of DM. 
Presence of pro-inflammatory state and endothelial dysfunction in DM 
are evidenced from previous studies 5. 
The rationale of this study is to evaluate the plasma MPO activity 
in type-2 DM patients and to study their correlation with lipid profile and 
glycated haemoglobin (HbA1c) levels of an individual. 
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AIMS AND OBJECTIVES 
Aim: 
The aim of the study was to estimate the plasma MPO activity in type-2 
DM patients and non-diabetic controls. 
 
Objectives: 
1. To compare the plasma MPO levels in 2 groups of subjects namely 
non-diabetic controls and type-2 diabetic patients. 
2. To study the correlation between plasma MPO activity and lipid 
profile in the study groups. 
3. To study the correlation between plasma MPO activity and HbA1c 
levels in the study population. 
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   REVIEW OF LITERATURE 
 
Introduction: 
Diabetes mellitus is the most common non-communicable disease 
worldwide 6. It describes a disorder of metabolism which is multifactorial 
in origin and characterised by chronic hyperglycemia. It is associated 
with metabolic disturbances related to carbohydrate, protein and fat 
which results from reduced insulin secretion or action or both 6.  
History of DM: 
Diabetes mellitus was first described in the Egyptian population. 
The term was first coined by Aertaeus, a Greek physician. The word 
diabetes meaning ‘to pass through’ in Greek was first used by Apollonius 
of Memphis in 250 BC. The word mellitus, the Latin word for honey was 
supplemented by Thomas Willis in 1600 to differentiate this disease from 
diabetes insipidus which was also linked with increased frequency of 
urination. 
The disease was identified by the ancient Indian physicians Charaka and 
Susruta who classified it as Madhumeha or honey urine. They described 
the differences in the clinical presentation of patients with Madhumeha: 
some patients were thin, had severe polyuria, thirst, dehydration and few 
others were short, obese, ate excess food and led inactive life. The two 
groups were later classified as type-1 and type-2 DM respectively 7. 
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` The role for pancreas in diabetes was revealed by Joseph von 
Mering and Oskar Minkowski in 1889 who established that when 
pancreatectomy was done in dogs they developed all features of diabetes 
and died shortly afterwards 8. Although diabetes has been known 
since pre-historic times and various effective treatments have been known 
in various parts of the world since the middle Ages, an effective treatment 
was developed after the Frederick Banting and Charles Best from 
Canada first used insulin in 1921 and 1922 7. 
Epidemiology of DM worldwide: 
DM is the most common endocrine disorder worldwide. Type-2 
DM accounts for more than 85% of diabetes cases in the world. In 2010, 
it was estimated that about 285 million people have diabetes in the world, 
of which 80% live in under developed countries 9. The maximum number 
of people with diabetes is 76 million and seen in the Western Pacific 
region. The area with highest prevalence rate of 11.7% is in North 
America 9.The number of people with diabetes worldwide is expected to 
reach 438 million by 2030 9. 
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Epidemiology of DM in India: 
DM is reaching an exponential rate of epidemic proportions in 
India. The level of burden due to diabetes as a disease and its potential 
complications are massive. It poses significant healthcare burdens on the 
society.  More than 62 million Indians are currently diagnosed with the 
condition 10. It has been predicted that by 2030 DM may affect up to 79.4 
million individuals in our country 11. The increased number of diabetics 
in India is mainly due to a significant increase in the incidence of type-2 
diabetes, caused by increased migration from rural to urban areas, which 
leads to changes in environmental and lifestyle 12. 
India recently is exposed to an uncertain future with regard to the 
possible burden that diabetes forces upon the society. Many factors affect 
the prevalence of the disease in a country and identification of those 
factors is necessary to bring about changes in order to face challenges in 
the health care system. 
Classification of DM: 
An international expert committee set certain regulations in June 
1997, and put forth new recommendations for the classification and 
diagnosis of DM 13. It was recognised that the terms IDDM and NIDDM, 
although superficially pleasing, were often confusing as in patients with 
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insulin treated Type-2 DM. Hence the terms insulin-dependent DM 
(IDDM) and non-insulin-dependent DM (NIDDM) were made out dated. 
The classification was revisited by World Health Organisation (WHO) in 
2006, but no further modifications were introduced.  
The current classification of DM is on the basis of the 
pathophysiological process that progress to hyperglycemia. The two main 
categories are designated type-1 and type-2. Both types go ahead by a 
phase of abnormal phase of glucose equilibrium as the pathological 
processes progress. Type-1 DM results from total or near-total absence of 
insulin. Type-2 DM is a diverse group of disease characterized by 
unpredictable levels of insulin resistance, impairment in insulin secretion 
and high glucose production. Various genetic and metabolic irregularities 
in insulin action or secretion or both are also found to contribute to the 
common characteristic of hyperglycemia observed in Type-2 DM. Type-2 
DM is ahead by an episode of abnormal glucose equilibrium state which 
is referred to as impaired fasting glucose (IFG) or impaired glucose 
tolerance (IGT). These two intermediate conditions were removed from 
the formal classification of types of diabetes-but were retained as a risk 
state. 
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Table 3.1:  Etiologic Classification of DM 
I. Type 1 diabetes ( caused by islet cell destruction which usually 
leads to total insulin deficiency) 
May be due to either immune-etiology or idiopathic 
II. Type-2 diabetes (can vary from insulin resistance to insulin 
deficiency which mainly occurs as a result of defect in 
secretion) 
III. Other specific types: 
A. Genetic defects of islet cell function characterized by mutations in: 
    1. Hepatocyte nuclear transcription factor- 4 (MODY 1) 
    2. Glucokinase (MODY 2) 
    3. Hepatocyte nuclear transcription factor -1 (MODY 3) 
    4. Insulin promoter factor-1 (MODY 4) 
    5. Hepatocyte nuclear transcription factor -1 (MODY 5) 
    6. NeuroD1 (MODY 6) 
    7. DNA of mitochondria 
    8. Subunits of ATP-sensitive potassium channel 
    9. Pro-insulin or insulin  
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B. Conditions which are caused by genetic defects in insulin action 
    1. Type A insulin resistance 
    2. Leprechaunism 
    3. Rabson-Mendenhall syndrome 
    4. Lipodystrophy syndromes 
C. Diseases of the exocrine pancreas—pancreatitis, pancreatectomy, 
neoplasia, cystic fibrosis, hemochromatosis, fibrocalculous 
pancreatopathy, mutations in carboxyl ester lipase 
  D. Endocrinopathies—acromegaly, Cushing's syndrome, glucagonoma, 
pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma 
  E. Drug or chemical induced - glucocorticoids, Vacor (a rodenticide), 
pentamidine, nicotinic acid,  diazoxide, β-adrenergic agonists, thiazides, 
hydantoins, asparaginase, α-interferon, protease inhibitors, anti-
psychotics (atypical and others), epinephrine 
  F. Infections—congenital rubella, cytomegalovirus, coxsackie virus 
  G. Uncommon forms of immune-mediated diabetes—"stiff-person" 
syndrome, anti-insulin receptor antibodies. 
  H. Other genetic syndromes sometimes associated with diabetes—
Wolfram’s syndrome, Down’s syndrome, Klinefelter’s syndrome, 
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Turner’s syndrome, Friedreich's ataxia, Huntington's chorea, Laurence-
Moon-Biedl syndrome, Myotonic dystrophy, Porphyria, Prader-Willi 
syndrome 
IV. Gestational diabetes mellitus 
 
Source: Adapted from American Diabetes Association, 2011. 
Other types of DM 
Other causes for DM consists of specific genetic defects in insulin 
secretion or action, metabolic irregularities that damage secretion of 
insulin, mitochondrial abnormalities and a whole lot of conditions which 
make worse the glucose tolerance which are listed in Table 3.1. Maturity 
onset diabetes of the young (MODY) is a sub-division of DM and is 
inherited as an autosomal dominant pattern. It is characterised by early 
age (<25 years) of onset of hyperglycemia and impaired insulin secretion. 
Mutations in insulin receptors are also found to cause a group of atypical 
disorders characterized by rigorous insulin resistance which leads to 
development of DM. 
DM can result from pancreatic exocrine dysfunction where there is 
predominant pancreatic islet cell destruction such as in pancreatitis. 
Hormones that oppose insulin action such as glucagon, growth hormone, 
cortisol can also lead to DM. Thus, acromegaly and Cushing's disease can 
11 
also manifest as DM. Viral infections such as cox-sackie virus have a 
major concern in pancreatic islet cell destruction but are extremely rare 
causes of DM 14. 
Gestational Diabetes Mellitus: 
Glucose intolerance has also been found to develop during 
pregnancy. There is increased predisposition towards insulin resistance, 
particularly in the last trimester of pregnancy. The increased requirement 
of insulin during pregnancy leads to impairment in glucose tolerance. 
Gestational diabetes occurs in approximately 4% of pregnancies. Most 
women revert to normal glucose tolerance after delivery. However, they 
develop a 30-60% significant risk of developing DM later in life 14. 
Impaired Glucose Tolerance (IGT): 
 IGT is diagnosed in people who have fasting blood glucose 
concentrations less than that required for diagnosis of DM, but have a 
plasma glucose response during the routine oral glucose tolerance test 
between that of a normal and diabetic state. An oral glucose tolerance test 
is required to diagnose a patient with this condition. 
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Impaired Fasting Glucose (IFG): 
IFG is similar to IGT and is diagnosed by a fasting glucose levels 
above normal but below that needed for diagnosis of DM. It is a 
metabolic stage between normal glucose homeostasis and DM.  
A diagnosis of IFG was defined as the fasting plasma glucose 
levels in the range of 100 mg/dL to 125 mg/dL.  
The criterion for the diagnosis of IGT is 2-hour values following 
the oral glucose tolerance test between 140 mg/dL to 199 mg/dL. 
Pre-diabetes refers to a state in which the patients are diagnosed 
with IFG or IGT conditions. These conditions designate the 
comparatively high threat for potential development of diabetes mellitus. 
They are viewed as risk factors for diabetes as well as cardiovascular 
disease. The natural history of both the conditions is variable. 25% of 
subjects with IFG or IGT can progress to apparent diabetes mellitus over 
3-5 years. 50% remain in their intermediate glycemic status and about 
25% regress to normal glucose tolerance over this period 15. Pre-diabetic 
individuals are at high risk for cardiovascular disease, as a result of the 
metabolic abnormalities related to carbohydrate, protein and lipids along 
with the existence of known cardiovascular risk factors such as sub-
normal levels of HDL cholesterol, increased levels of triglycerides and 
LDL cholesterol 16. 
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ADA 2010 Criteria for the diagnosis of type-2 diabetes mellitus:  
1. Fasting plasma glucose    ≥     126 mg/dL.  
Fasting is defined as no caloric intake for at least 8 hours. 
OR 
2. 2 hour plasma glucose     ≥    200 mg/dL during an oral glucose 
tolerance test.  
The test should be performed using a glucose load containing 
the equivalent of 75 grams anhydrous glucose dissolved in 
water, not recommended for routine clinical use. 
OR 
3. In a patient with classic symptoms of hyperglycemia or 
hyperglycemic crisis, a random plasma glucose   ≥   200 mg/dL. 
Random is defined as without regard to time since the last meal. 
OR 
4. HbA1c   ≥    6.5%.  
The test should be performed in a laboratory using a method 
that is certified by the National Glycohemoglobin 
Standardization Program and standardized to the Diabetes 
Control and Complications Trial assay. 
*In the absence of unequivocal hyperglycemia and acute metabolic 
decompensation, these criteria should be confirmed by repeat 
testing on a different day 17. 
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Glycated haemoglobin (HbA1c):  
Glycated haemoglobin has been well-known as an index of blood 
glucose levels over a prolonged phase of time. It is an evaluation of risk 
for the evolution of complications in patients with DM.  
 
Chemically, glycation is the addition of a sugar residue to amino 
groups of proteins which occurs spontaneously without the need for an 
enzyme. Human adult haemoglobin usually consists of HbA, HbA2 and 
HbF which comprises of about 97%, 2.5% and 0.5% each of the total 
hemoglobin respectively HbA is made up of four polypeptide chains, two 
α and two β chains. HbA1c is formed by reaction of glucose with the N-
terminal valine residue of any one of the β-chains of HbA to form an 
unstable Schiff base. The Schiff base formation is reversible. This 
undergoes Amadori rearrangement to form a stable conjugate referred to 
as glycated haemoglobin. This reaction when it occurs between glucose 
and other proteins leads to the synthesis of advanced glycation end 
products (AGE) which contributes to the micro and macro vascular 
complications of DM. Glycation of collagen is found to alter its 
biological properties thereby increases cross linking and leads to the 
formation of brittle collagen. Adhesion of plasma proteins in the altered 
blood vessels leads to accumulation of LDL and consequent 
atherosclerosis.  
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After a broad review of recognized and rising epidemiological 
verification, an International Expert Committee, suggested to employ the 
HbA1c test to establish a diagnosis of diabetes. The cut-off limit was set 
at a level of 6.5%. This test is considered valid if done using method 
qualified by the National Glycohemoglobin Standardization Program. 
The American Diabetes Association acknowledged this decision. The 
traceability of the method should be to the Diabetes Control and 
Complications Trial reference assay 18. 
 
Major risk factors for Type-2 DM:  
Table 3.2: Risk Factors for Type-2 DM 
Family history of diabetes ( parent or sibling with Type-2 DM)  
Obesity (Body mass index (BMI  ≥   25 kg/m2)  
Physical inactivity  
Race/ethnicity (African American, Latino, Native American, 
Asian American, Pacific Islander)  
Previously identified with IFG,  IGT or HbA1c of 5.7-6.4% 
History of Gestational diabetes or delivery of baby >4 kilograms 
Hypertension (blood pressure ≥ 140/90 mmHg)  
HDL cholesterol level < 35 mg/dL 
Triglyceride level > 250 mg/dL 
16 
Polycystic ovary syndrome or acanthosis nigricans 
History of cardio-vascular disease 
 
Source: Adapted from American Diabetes Association, 2011. 
Pathogenesis of Type-2 DM: 
Type-2 DM is a heterogenous disorder, phenotypically, genotypically 
and pathogenetically. The most common form of type-2 DM is found to 
be the outcome of a grouping of genetic and acquired factors which 
negatively affect beta cell function and sensitivity of tissues to insulin 19. 
For some years it was notorious whether impairment of the functions of 
beta cell or resistance to insulin action in peripheral tissues was the 
underlying fundamental element. The idea that insulin resistance was the 
basic defect had been traced back to the classic studies of Himsworth and 
Kerr 20. Insulin resistance was found to result from the interplay of 
numerous genetic and environmental factors. 
 Insulin resistance: Insulin resistance is defined as lack of ability 
of insulin to produce its typical biological functions at effective 
circulating levels in normal subjects 21. It is found in non-diabetic 
individuals who are obese and in patients with Type-2 DM. It is 
usually attributed to defective insulin action. There is a broad 
scientific continuum of insulin resistance that varies from 
euglycemia with a remarkable increase in insulin secretion by the 
17 
pancreatic islet cells to hyperglycemia in spite of increased doses 
of exogenous insulin. 
 Loss of beta-cell function: The impairment of beta cell function is 
associated with the insulin resistance mediated increased beta-cell 
demand that is required for developing fasting hyperglycemia. The 
major defect is loss of secretion of insulin which is induced by 
glucose termed selective glucose insensitivity. Excess increase in 
blood glucose levels renders the beta cells insensitive to glucose. 
The extent of beta cell dysfunction is found to be associated with 
both glucose concentration and duration of hyperglycemia. The 
normal pulsatile secretion of insulin is also found to be disturbed. 
 Diabetogenes: Genetic factors also contribute to the development 
of diabetes. Type-2 diabetes is a polygenic disorder which means 
that multiple genetic polymorphisms must be there with or without 
acquired abnormalities in order to cause diabetes. Genes that affect 
beta cell apoptosis, beta cell regeneration, sensing glucose levels, 
ion channels, energy transduction, microtubules or microfilaments, 
metabolism of glucose and other islet proteins mandatory for the 
synthesis, binding, progress and discharge of secretory granules 22. 
Until recently, only a small number of polymorphisms have been 
identified as risk factors: One involves amino acid genetic 
variations in the peroxisome proliferator activated receptor gamma 
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which is expressed in target tissues of insulin action and beta cells. 
Second involves the gene encoding a cysteine protease namely 
calpain-10, which modulates insulin release as well as insulin 
actions on skeletal muscle and adipose tissue 23. Multiple genetic 
influences interact with exogenous factors such as environmental 
agents to produce the diabetic state of the individual. However, 
despite extensive efforts, the gene or genes causing the frequent 
form of Type-2 diabetes remains indefinite. 
 Environment: Environmental factors ranging from dietary habits 
to level of physical activity are chief determinants in the 
development of Type-2 DM. Obesity is associated with insulin 
insensitivity and is the most significant predictive risk factor for 
development of Type-2 DM. It is found to be mediated by a variety 
of factors released from adipose tissue such as leptin, adiponectin 
and many others which adversely affect functions of beta cell. An 
inverse relationship exists between the level of physical activity 
and the prevalence of Type-2 DM. Exercise is thought to produce 
an increased sensitivity to insulin in skeletal muscle and adipose 
tissue. 
Dyslipidemia in diabetes mellitus: 
Insulin resistance in the perception of glucose metabolism 
leads to impairment in the suppression of endogenous glucose 
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production under basal and fasting conditions. It also leads to 
reduced peripheral uptake of glucose. Insulin suppresses the 
production of very low density lipoprotein (VLDL). Resistance to 
this action of insulin increases circulating serum triglycerides 
levels. Resistance to insulin action in the adipose tissue increases 
the discharge of non-esterified fatty acids (NEFA) both to the liver 
and skeletal muscle. This impairs the actions of insulin on glucose 
metabolism in these tissues. Evidence from previous studies 24 
suggested that insulin normally suppresses the production of 
VLDL, especially VLDL -1 apo-B particles from the liver. This 
effect is brought about by decrease in availability of non-esterified 
fatty acids and also a direct effect of insulin on the liver cells where 
it inhibits the assembly and synthesis of VLDL particles 25. In 
discrepancy to normal subjects, insulin fails to restrain VLDL apo-
B production in those with Type-2 DM, though insulin profoundly 
lowers NEFA concentrations. Overproduction of VLDL and the 
defective insulin mediated inhibition of VLDL production are 
found to be one major causative mechanism for the increase in 
serum triglyceride concentrations in patients with insulin resistant 
Type-2 DM 26.  
HDL levels are reduced in patients with insulin resistance 
accompanied by high serum triglycerides. There is increased 
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exchange of cholesteryl esters and triglycerides, between HDL and 
other lipoproteins that are rich in triglyceride, by cholesterol ester 
transfer protein (CETP) in conditions producing a 
hypertriglyceridemic state 27. Finally the HDL particles are 
enriched with triglycerides which make them susceptible to the 
action of hepatic lipase. This clears HDL particles from the 
circulation at an increased rate. Further subnormal activity of 
lipoprotein lipase (LPL) leads to further fall in HDL cholesterol 
levels still further by decreasing the inter-conversion of HDL-3 to 
HDL-2 particles 27.  
Elevated concentrations of VLDL particles in diabetic 
patients also increase the exchange of cholesterol ester and 
triglyceride between VLDL and LDL cholesterol particles 
mediated by CETP. This increases the triglyceride content of LDL 
particles which makes them more susceptible for the action of 
hepatic lipase 28. This enzyme hydrolyses triglycerides present in 
the LDL particles thereby increasing their density. This sequence 
of events explains why Type-2 DM individuals have smaller and 
denser LDL particles than individuals without diabetes 29. The 
small dense LDL particles are found to be highly atherogenic and 
provide a possible association between insulin resistance and 
cardiovascular disease 30. 
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Metabolic derangements in diabetes: 
Carbohydrate metabolism in Type-2 DM: 
People with Type-2 DM have fasting hyperglycemia and excessive 
variations in glucose levels following ingestion of a carbohydrate rich 
meal. In these patients insulin secretion is typically reduced and slow 
following food ingestion. Defects in insulin secretion are usually 
observed early in the evolution of Type-2 DM. In fact, variations in 
timing and amount of insulin secreted by the pancreatic beta cells have 
been reported in relatives of diabetic patients preceding the development 
of hyperglycemia. 
Chronic hyperglycemia in combination with elevated free fatty 
acid levels impairs insulin secretion. Abnormalities in sensing glucose 
levels, processing of insulin or intracellular signalling modify insulin 
secretion. In addition, the mass of the pancreatic β-cell decrease with 
increase in the duration of diabetes. Alterations in β-cell morphology 
occur in most people with Type-2 DM with extensive intra-islet cell 
deposition of amylin commonly being observed 31.  
Defects in insulin secretion and action are found to contribute to 
post-prandial rise in blood glucose levels. A delay in the rise of insulin 
concentration causes a delay in control of glucose production. This in turn 
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results in excessive glycemic variations. Also, a defect in insulin action 
leads to sustained hyperglycemia32. 
Glucose is an important regulator of its own metabolism. In the 
presence of insulin at basal levels, an increase in plasma glucose 
concentration stimulates uptake of glucose and suppresses its endogenous 
production. This ability of glucose to regulate its own metabolism is 
impaired in Type-2 DM. This is referred to as a defect in glucose 
effectiveness. The resulting excess increase in glucose is caused by 
impairment of glucose induced stimulation of glucose uptake 33.  
Inhibition of glucagon secretion lowers both fasting and post-
prandial blood glucose levels. When insulin secretion is intact, failure to 
suppress glucagon secretion has only minimal effect on glucose level 
regulation. In Type-2 DM in which insulin secretion is decreased and 
delayed glucagon causes marked hyperglycemia34. 
Amylin is a polypeptide made up of 37 amino acids. It is secreted by the 
pancreatic beta cell along with insulin in response to stimuli. Human 
studies have shown that plasma levels of amylin and insulin are found to 
rise and fall in parallel in both the fasting and fed states 35. It has been 
implicated that excessive secretion of amylin may contribute to beta cell 
destruction in Type-2 DM.  
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In addition to defective insulin secretion, people with Type-2 DM 
frequently reveal defective insulin action. Several studies have shown that 
impairment of the suppression of glucose synthesis that is induce by 
insulin and stimulation of use of glucose in skeletal muscle and adipose 
tissue occurs in Type-2 DM 36, 37. The severity of resistance to insulin 
action is influenced by several exogenous factors including exercise, 
obesity, diet and also genetic factors. Insulin resistance increases with 
increased severity of diabetes and improves by better glycemic control 38. 
Defects in the capacity of insulin to regulate glucose metabolism in 
muscle and adipose tissue are evident in normoglycemic relatives of 
diabetic patients strongly favouring a genetic basis for insulin resistance.  
Lipid metabolism in Type-2 DM: 
Triglycerides are an important source of energy and storage form 
of lipids. They are mobilized as free fatty acids (FFA). Plasma FFA 
concentrations represent an equilibrium between their release and 
clearance. FFA are taken up and re-esterified in adipose tissue and 
hepatic cells. Some get oxidized in muscle (either cardiac or skeletal) and 
also in the liver. They are released from intravascular digestion of 
lipoproteins like chylomicrons which are rich in triglycerides and intra-
adipocyte lipolysis of triglyceride stores. FFA concentrations are 
determined largely by its rate of access into circulation in fasting state. In 
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the post-prandial phase its rate of usage by both adipose and hepatic 
tissues also contributes to the FFA concentrations 39. 
Hormone-sensitive lipase is the primary regulator in adipose tissue 
for the release of FFA. It is extremely sensitive to the hormonal actions of 
the principal regulator of lipolysis, which is insulin. Increased insulin 
secretion following an increase in glucose concentration after a meal 
inhibits lipolysis. This leads to a decreased in plasma FFA concentrations. 
It thus enhances insulin-dependent glucose clearance and insulin-induced 
suppression of endogenous glucose production 40.  
In individuals with diabetes, the ability of insulin to suppress 
lipolysis is impaired, probably because of decreased sensitivity of 
hormone-sensitive lipase to insulin. The resulting increase in FFA tends 
to increase the blood glucose concentrations. Insulin also promotes FFA 
disposal by stimulating re-esterification in adipose tissue to form 
triglycerides. This is dependent on the availability of glycerol-3-
phosphate derived from insulin induced uptake of glucose and intra-
adipocyte glycolysis.  
Circulating plasma triglyceride levels depends on the activity of 
LPL to deliver FFA to the adipose tissue. Insulin and glucose 
preferentially stimulate LPL in the adipose tissue and inhibit that present 
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in the muscle. It thus separates triglyceride-derived and lipoprotein-
derived fatty acids away from muscle and into adipose tissue 41.  
In Type-2 DM, insulin-induced activation of LPL in adipose tissue 
is delayed whereas there is activation of skeletal muscle LPL. FFA 
decrease glucose uptake in muscle by inhibiting glucose transport, 
glucose phosphorylation and muscle glycogen synthase 42. Elevated FFA 
stimulates gluconeogenesis in liver and synthesis of triglycerides. Acute 
rise in FFA stimulates insulin secretion whereas chronic rise inhibits 
insulin secretion 43. Thus, elevated FFA has been implicated in many of 
the metabolic abnormalities associated with Type-2 DM.  
Protein metabolism in Type-2 DM: 
Protein metabolism at any given time is generally regulated by 
substrate availability and the hormonal milieu. Insulin is found to have 
profound influence over protein metabolism. People with Type-2 DM 
have sufficient left over insulin secretion to limit protein breakdown and 
maintain lean body mass. On the other hand, whole body nitrogen flux, 
protein synthesis and breakdown are increased in poorly controlled 
diabetic patients. Improvement in glycemic control by treatment with 
either oral hypoglycemic agents or insulin restores these defects to 
normal.  
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Few studies have examined regional protein dynamics in Type-2 
DM. 3-methylhistidine excretion, an index of myofibrillar protein 
breakdown has been found to be increased in individuals with poor 
control of their diabetic status when differentiated from healthy 
subjects44. Improvement in glycemic control decreased 3-methylhistidine 
excretion. Clotting factors such as tissue plasminogen activator are found 
in elevated concentrations in diabetic patients. In addition levels of 
plasminogen activator inhibitor-1 (PAI-1) are also increased in these 
individuals.   This implies that the synthesis of certain proteins by the 
hepatocytes and endothelial cells is abnormal. This provides additional 
evidence of the increased threat of cardiovascular complications in 
diabetic individuals 45. 
Complications of DM: 
The majority of the burden due to the morbidities associated with type-2 
DM is the result of the plethora of complications which ensues the 
development of the disease. The most common complications associated 
with it are classified as acute and chronic based on their mode of onset. 
Acute complications: 
1. Diabetic ketoacidosis:  
Ketosis is more common in type 1 DM. The normal level of 
ketone bodies in blood is less than 1 mg/dL and only traces get 
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excreted in urine. When rate of synthesis exceeds the ability of 
extrahepatic tissues to utilize them, they get accumulated in 
blood. The combination of hyperglycemia, glucosuria, 
ketonuria, and ketonemia is called diabetic ketoacidosis. 
Untreated DM is the most common cause for ketosis. 
2. Hyperglycemic Hyperosmolar State:  
The primary defects in this condition are a relative state of 
insulin deficiency and too little fluid intake. Deficiency state of 
insulin increases hepatic glucose production which occurs 
endogenously through glycogen breakdown and 
gluconeogenesis. It also impairs uptake of glucose in skeletal 
muscle. Hyperglycemia induces an osmotic diuretic state which 
leads to depletion of the intravascular fluid compartment. This 
is further exacerbated by inadequate fluid replacement. The 
absence of ketosis in this condition is not completely 
understood.  
Chronic complications of DM: 
The chronic complications of DM are known to affect 
various organ systems. They can be divided into vascular and non-
vascular complications (Table 3.3).  
Table 3.3:  Vascular
Microvascular 
Eye disease 
    Retinopathy may be non
    Macular edema
Neuropathy 
   Sensory and motor 
   Autonomic 
Nephropathy 
Macrovascular
Cardiovascular disease
Peripheral arterial disease
Cerebrovascular disease
Others 
Gastrointestinal dysfunction such as gastroparesis, diarrhea
Genitourinary abnormalities
Dermatologic manifestations
Infections 
Cataract 
Glaucoma 
Periodontal disease
Hearing loss 
Source: Harrison’s Principles of Internal Medicine 18
2980. Alvin C Powers. Diabetes Mellitus
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 The risk of chronic complications increases with duration of 
hyperglycemia. Since Type-2 DM often is preceded by a long disease free 
period without any symptoms of hyperglycemia, many patients present 
with complications at the moment of diagnosis. 
The micro-vascular complications of Type-2 DM are found to 
result from chronic hyperglycemia. Genetic susceptibility also has a 
predominant contribution to the pathogenesis of complications in diabetic 
patients. The role for chronic hyperglycemia in the development of 
macro-vascular complications is not much evident. However, coronary 
heart disease events and mortality are two to four times greater in patients 
with Type-2 DM. These events are also found to correlate with fasting, 
postprandial glucose levels in the blood and also with the HbA1c. Other 
factors such as dyslipidemia and hypertension are also found to play 
important roles in development of vascular complications in diabetic 
patients 46. 
Pathogenesis of vascular complications in DM:  
             Chronic hyperglycemia has been implicated as an important 
etiologic factor in the development of diabetic complications. Four 
theories were put-forth to explain the mechanisms by which it leads to 
such varied dysfunction of the cells and organs. One recent emerging 
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hypothesis suggests that hyperglycemia leads to epigenetic changes in the 
affected cells. 
          One theory is that chronic hyperglycemia can progress to the 
formation of AGE via the non-enzymatic protein glycation. This results 
from the condensation of glucose with amino groups present in proteins. 
AGE are found to cross-link extra cellular matrix proteins such as 
collagen. These glycated proteins are found to modify the composition 
and functions of the extracellular matrix and also exhibit a wide variety of 
effects on the vascular system such as decreased synthesis of nitric oxide, 
acceleration of atherosclerosis, glomerular dysfunction through 
modification of basement membrane proteins. 
          Second theory suggests that excess glucose that results from insulin 
deficiency is channelized into the sorbitol pathway. Normal metabolism 
of glucose inside the cells is usually by phosphorylation and subsequent 
glycolysis. When glucose levels are increased, it gets converted to 
sorbitol by the enzymatic action of aldose reductase. Increased 
concentration of sorbitol alters the redox potential, increases the cellular 
osmolality and also generates reactive oxygen species which in turn leads 
to cellular dysfunction.  
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 The third hypothesis suggests that increased glucose levels in the blood 
increases the production of diacylglycerol. This activates the protein 
kinase-C (PK-C) signal transduction pathway. PK-C alters the 
transcription of genes for fibronectin, type IV collagen, contractile 
proteins and other proteins of the extracellular matrix present in 
endothelial cells and neurons.  
        A fourth presumption proposes that excess blood glucose leads to a 
major flux through the hexosamine pathway. This generates fructose-6-
phosphate, a substrate for O-linked glycosylation and production of 
proteoglycans. This leads to glycosylation of proteins such as endothelial 
nitric oxide synthase or alters functions of certain proteins by regulating 
gene expression of transforming growth factor or PAI-1. Increased 
production of growth factors by one of the above proposed mechanisms is 
found to contribute to the vascular complications of DM. 
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Figure 3.1: Pathogenesis of vascular complications in DM 
 
Source - Brownlee M. Pathobiology of diabetic complications. Nature 414: 2001; 
813-820. 
A possible unifying mechanism that leads to diabetic complications 
is that, raised blood glucose levels due to insulin deficiency or insulin 
resistance leads to increased creation of reactive oxygen species or 
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superoxide radicals in the mitochondria. These free radicals were found 
to be responsible for the deleterious effects on organ systems 47. 
Cardiovascular morbidity in DM: 
Diabetic patients are 2 to 4 times more likely to succumb to the 
drastic effects heart disease than non-diabetics. More than 70% of 
mortality in diabetic patients is attributed to cardiovascular disease 
(CVD) 48. DM has been identified as a major risk factor for CVD by The 
American Heart Association. Patients with CVD and co-existing DM 
have a worse prognosis than that for non-diabetics. Further, multiple 
vessel involvement in CVD is more likely in individuals with DM.  
The co-existence of hyperglycemia along with other major 
cardiovascular risk factors contributes to the increase in cardiovascular 
system related morbidity and mortality in diabetic individuals. The other 
major risk factors for macro-vascular disease in diabetic individuals 
include altered lipid profile, associated systemic hypertension, 
overweight and obesity, sedentary lifestyle and smoking habits. Further 
certain alterations in biochemical parameters more prevalent in diabetic 
patients also pose an additional risk to these individuals. These include 
micro and macroalbuminuria, elevation of serum creatinine levels and 
dysfunctional platelet activity. Insulin resistance itself is a well-
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established risk factor for cardiovascular complications in individuals 
with or without DM. These individuals have raised levels of plasminogen 
activator inhibitors (especially PAI-1) and fibrinogen which enhances the 
coagulation process and impairs fibrinolysis thus favouring development 
of thrombus in the vasculature. The underlying mechanism for the 
increased cardiovascular morbidity in DM is accelerated atherosclerosis. 
The process of atherosclerosis starts from the formation of a fatty streak 
that gradually progresses into more advanced plaques. It terminates in 
complicated lesions of atherosclerosis, which through rupture and 
thrombus formation can lead to acute myocardial infarction. 
Atherosclerosis:  
It is characterized by lesions in the endothelial intimal layer called 
atheromas or atherosclerotic plaques that project into vessel wall lumen. 
An atheromatous plaque is a raised lesion made up of a central core of 
lipid which is made up of predominantly cholesterol and its esters 
covered by a white fibrous cap. Apart from obstructing blood flow by 
mechanical means, these plaques rupture and lead to distressing vessel 
thrombosis. It can also deteriorate the underlying media thus leading to 
formation of aneurysm 49. Hyperlipidemia is one of the most important 
risk factor for atherosclerosis. The mechanism by which hyperlipidemia 
contributes to atherogenesis include thefollowing: 
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Stage 1: Formation of foam cells: 
Chronic hyperlipidemia, especially increase in cholesterol levels 
can directly produce endothelial dysfunction by increasing free radical 
production locally. These reactive radicals can cause injury to the tissues 
and accelerates decay of nitric oxide thereby reducing its vasodilator 
activity. 
Lipoproteins accumulate within the intima in hyperlipidemic 
conditions. They get oxidized through the action of oxygen free radicals 
generated locally by macrophages or endothelial cells. Oxidized LDL is 
ingested by macrophages through a scavenger receptor and accumulates 
in phagocytes which are further referred to as foam cells. Further, 
oxidation of LDL provokes the release of various growth factors, 
cytokines and chemokines by endothelial cells and macrophages. This 
increases further monocyte recruitment into atherosclerotic lesions. 
Finally, oxidized LDL is toxic to endothelial cells and smooth muscle 
cells and thus induces dysfunction of the endothelial cell. Accumulation 
of this modified LDL within macrophages in various stages of plaque 
formation reveals its importance in atherogenesis. 
 
Stage 2: Progression of atherosclerosis: Smooth muscle cells 
containing lipid droplets are seen in the lesion. The condition is reversible 
in the early stages if lipid levels especially that of LDL is lowered. 
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However when lipid is accumulated, the lesion progresses and the arterial 
changes become irreversible.  
 
Stage 3: Fibrous proliferation: There is a definite component of 
inflammation in atherosclerosis. Dysfunctional endothelial cells in the 
major arteries express a variety of adhesion molecules, particularly 
vascular cell adhesion molecule-1 which binds to monocytes and T-cells. 
These cells adhere to the endothelium; migrate into the intima under the 
control of locally produced chemokines. The transformation of 
macrophages into monocytes into macrophages leads to engulfment of 
lipoproteins, including oxidized LDL. Progressive accumulation of 
oxidized LDL promotes lesion development. Macrophage activation 
results in cytokine production which further increases adhesion of 
leukocyte and chemokine production. It also produces reactive oxygen 
species, aggravating LDL oxidation. T-lymphocytes that are recruited to 
the intima interact with macrophages and generates a chronic 
inflammatory state. However, activated T-cells elaborate inflammatory 
cytokines. This process stimulates macrophages, endothelial cells and 
smooth muscle cells proliferation mediated by various growth factors. 
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Stage 4: Advancing fibrous plaque: This leads to contraction of the 
blood vessel wall leading to more turbulent blood flow and increased 
tendency to clot formation 50.  
Table 3.4: Major risk factors in development of atherosclerosis: 
Modifiable Non-Modifiable 
Increased lipid levels in blood 
Systemic hypertension 
Diabetes 
Smoking – Tobacco 
Advancing age 
Males  
Individuals with family history 
Genetic defects 
Source: Kumar, Abbas, Fausto, et al. Robbins and Cotran Pathologic Basis of 
Disease, 8th Edition, Chapter 11, Blood Vessels, Richard N Mitchell, Frederick J 
Schoen, Elsevies- Saunders, Philadelphia, 2010: 497.  
 
 
Figure 3.2: Sequence of cellular interactions in atherosclerosis 
 
Source: Kumar, Abbas, Fausto, et al. Robbins and Cotran Pathologic Basis of 
Disease, 8th Edition, Chapter 11, Blood Vessels, Richard N Mitchell, Frederick J 
Schoen, Elsevies- Saunders, Philadelphia, 2010: 501. 
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Risk factors such as hyperlipidemia cause injury to the endothelial 
cells which results in sticking together of platelets and monocytes and 
release of growth factors which leads to smooth muscle cell migration 
and proliferation like platelet-derived growth factor. Macrophages and 
smooth muscle cells transform to foam cells that constitute the 
atheromatous plaques. It is derived from macrophages via the VLDL 
receptor. In conditions of increased cholesterol levels, the extracellular 
lipid is derived from accumulation in the vessel lumen and also from 
degenerating foam cells. Accumulation of cholesterol in the plaque 
reflects a disparity between the rate of its entry and exit from the 
circulation. HDL helps to clear the cholesterol resulting from these 
accumulations. Smooth muscle cells migrate to the intimal layer of the 
blood vessels, proliferate in it and produce extracellular matrix proteins, 
like collagen and proteoglycans 49. 
 
Endothelial dysfunction in diabetes mellitus: 
The increased occurrence of cardiovascular disease in diabetic 
patients is generally attributed to the unfavourable effects of 
hyperglycemia and oxidative stress. It has been revealed that pre-diabetic 
conditions, such as IFG and IGT pose an increased risk for development 
of cardiovascular disease 16. Atherosclerosis which has been implicated in 
its pathogenesis is found to arise because of vascular endothelial cell 
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dysfunction due to the prevalence of any individual risk sources listed in 
Table 3.4. 
 
Vascular endothelial cells are found to play a crucial role in 
maintaining cardiovascular environment. In addition to providing a 
physical obstacle between vessel wall and lumen, it also secretes 
numerous mediators which are found to control aggregation of platelets, 
coagulation process and vessel tone. They also produce various mediators 
which alternately mediate either vasoconstriction such as endothelin-1 
and thromboxane A2 or vasodilatation such as nitric oxide, prostacyclins 
and endothelium-derived hyperpolarizing factor. In larger arteries nitric 
oxide is the major contributor to endothelium-dependent relaxation, 
whereas in the smaller resistance vessels contribution of endothelium-
derived hyperpolarizing factor predominates 51.  
 
Patho-physiology of endothelial dysfunction in Type-2 DM: 
The main functions of endothelial cells are altered in Type-2 DM. 
There are a number of mechanisms for the commencement of impaired 
function of endothelium in type-2 diabetes described including 
hyperglycemia, formation of AGE and dyslipidemia. 
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Hyperglycemia:  
Hyperglycemia contributes to endothelial dysfunction in a number 
of ways. Decreased activity of pentose phosphate pathway leads to 
limited availability of NADPH, a necessary cofactor for endothelial nitric 
oxide synthase which can cause reduced production of nitric oxide. 
Increased glucose transport across endothelial cell membranes leads to 
increased flux through polyol pathway. As a consequence glucose is 
reduced to sorbitol by aldose reductase, leading to a further depletion of 
NADPH. Sorbitol undergoes oxidation to fructose by sorbitol 
dehydrogenase enzyme. This reaction uses NAD+, resulting in 
amplification of NADH/NAD+ ratio, thereby leading to modification of 
the redox state of the cells. This results in oxidative stress, which 
promotes generation of superoxide anions which further quenches nitric 
oxide, reducing its bioavailability 52. 
 
Formation of AGE: 
Hyperglycemia increases the denovo synthesis of diacylglycerol by 
enhancing metabolism of glucose to diacylglycerol precursors through 
glycolysis. The diacylglycerol activates an important signal transducer 
namely PK-C. This leads to decrease in enzymatic activity of nitric oxide 
synthase, especially the endothelial isoform and an increase in the 
production of prostaglandin like substances by the endothelium 53. PK-C 
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promotes generation of superoxide anions, which reacts with nitric oxide 
to produce peroxy-nitrite (ONOO-) which damages adjacent tissues. The 
amplified production of endothelin-1 due to the increase in glucose levels 
via activation of the β and δ isoforms of PK-C leads to its increased 
concentration in Type-2 DM 54. The PK-C leads to the migration and 
proliferation of smooth muscle cells by increasing the production of 
growth factors by the endothelium,. 
Hyperglycemia produces vascular dysfunction due to the 
interaction of AGE with their specific receptors on the endothelium. AGE 
quench the nitric oxide and increases the susceptibility of LDL to 
oxidation. The AGE and their receptors interact with each other which 
lead to a rise in thrombomodulin and activate the receptors for the 
numerous cytokines such as interleukin-1, tumour necrosis factor-α and 
growth factors leading to the migration and proliferation of smooth 
muscle cells. Other cell adhesion molecules are also increased related to 
hyperglycemia. This alters the vascular permeability which in turn 
favours the transmigration of mononuclear cells and the change of 
monocytes to macrophages which finally become foam cells of the 
atherosclerotic plaque 55. 
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Oxidative stress and diabetes mellitus: 
Oxidative stress results from a disproportion between an 
augmented generation of oxidant compounds and inadequate anti-oxidant 
defence mechanisms which lead ultimately to tissue damage 56. 
Generation of oxidant compounds is physiologically relevant as a defence 
mechanism against invading microorganisms, cancer cells and also in 
tissue healing and remodelling. Dysfunction in the oxidative mechanisms 
can contribute to cell injury and death. 
 
Sources of oxidative stress: 
The respiratory chain of mitochondria represents the most potent 
source of oxidants in the body. These oxidants exert deteriorating effects 
contributing to aging of the cells and tissue damage. The phagocytes in 
response to a suitable stimuli leads to the production of oxidants based on 
the stimulated production of reactive oxygen species via univalent 
reduction of oxygen at the molecular level. This leads to the activation of 
polymorphonuclear neutrophils, monocyte and macrophages to increase 
their oxygen consumption. This phenomenon is referred to as the 
respiratory burst.  
The NADPH oxidase enzyme system remains attached to cellular 
membranes. It reduces molecular oxygen to the highly unstable 
superoxide anion (O2
-
·), by its enzymatic action which finally gets 
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transformed into hydrogen peroxide. Both O2
-
·and hydrogen peroxide 
serve as important precursors for the synthesis of potent oxidants. 
Superoxide anion reacts with nitric oxide to produce highly reactive 
nitrogen species. Hydrogen peroxide, through Fenton’s reaction reacts 
with intracellular iron to produce the hydroxyl radical 57. Hydrogen 
peroxide oxidises ferrous iron (Fe2+) to ferric form (Fe3+), a hydroxyl 
radical along with a hydroxyl anion. This is followed by the reduction of 
the ferric form to ferrous, a superoxide radical and a proton by the same 
hydrogen peroxide. 
(1) Fe2+ (Ferrous) + H2O2 +H
+ → Fe3+ (Ferric) + HO•(hydroxyl  radical)  
+ H2O  
(2) Fe3+ H2O2 + → Fe
2+ + HOO• (Superoxide radical) + H+ (proton) 
These reactions have been concerned in degeneration of the lipid cell 
membrane, protein aggregation and DNA damage. 
Hydrogen peroxide is the substrate for MPO to produce the 
chlorinated oxidants. In the presence of chlorine, MPO converts hydrogen 
peroxide into hypochlorous acid. This is a powerful compound capable of 
inducing the oxidation a number of molecules like lipids, proteoglycans 
and other membrane proteins or intracellular constituents, particularly the 
thiol group of membrane proteins. In addition, hypochlorous acid reacts 
with endogenous amines to form chloramine derivatives. The reactive 
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oxygen species are released together with pro-inflammatory cytokines, 
which again magnifies further oxidant generation. 
 
Oxidative stress markers and antioxidants: 
Oxidants are compounds which are highly reactive. They have a 
very short half-life of only a few seconds. Therefore, their estimation in-
vivo is generally not possible. In contrast modification of lipids, proteins, 
carbohydrates and nucleic acids, by oxy-radicals, have biological activity 
ranging from hours to weeks. Thus they serve as ideal markers of oxidant 
stress 58. 
Table 3.5: Markers of oxidative stress and anti-oxidants: 
Oxidative stress markers Anti-oxidants 
1. Lipid peroxidation: 
Acrolein, Malondialdehyde, 
4-hydroxynonenal, 
thiobarbituric acid reactive 
substances, Advanced lipid 
oxidation products, Oxidised 
LDL antibodies 
2. Protein oxidation: 
Advanced protein oxidation 
products 
1. Enzymatic 
Superoxide dismutase 
Catalase 
Glutathione peroxidase 
2. Non-enzymatic 
Glutathione 
Vitamin C 
Vitamin E 
Ferritin 
Transferrin 
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3. Carbohydrate oxidation: 
Advanced glycation end 
products 
4. Nucleic acid oxidation: 
8-hydroxy-2’ 
deoxyguanosine 
Albumin 
 
 
Role of oxidative stress in the pathogenesis of diabetes and diabetic 
complications: 
 
The mechanisms of free-radical production in diabetes include 
glucose auto-oxidation, protein glycation, AGE formation and activation 
of polyol pathway. All these pathways ultimately lead to an oxidative 
stress in a number of tissues 59. The lack of appropriate compensatory 
mechanisms from natural in-vivo antioxidant system produces an 
imbalance in the redox state of the cell. This leads to the activation of 
intracellular signalling pathways. The increased generation of reactive 
oxygen species causes damage of proteins, lipids and nucleic acids. 
Further the activation of signalling pathways known to regulate gene 
expression also leads to cellular damage 60.  
Lipid peroxidation produced by the activity of free radicals play a 
major role in the development of diabetic complications. Lipids combine 
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with free radicals and undergo peroxidation. This leads to the formation 
of lipid peroxides which on decomposition form numerous by-products 
including malondialdehyde. This modified lipids after peroxidation 
decreases the membrane fluidity which leads to a dysfunction in the 
plasma membrane. It also changes the activity of membrane bound 
proteins. The lipid peroxidation products are harmful to every cell in the 
body and are related with a diversity of diseases including DM. 
 
Inflammation in DM: 
 Inflammation has been proposed to be important supplementary causal 
factors in the progress of Type-2 DM. The central mechanism by which 
inflammation and stress are found to mediate insulin resistance is through 
the inhibition of insulin receptor signalling pathways. 
The cells of the adipose tissue are an important source of storage of lipids 
and help in regulation of homeostatic environment for metabolism. It also 
regulates the functions of macrophages in inflammation. In obesity, there 
is inflammation of adipose tissue. This leads to an infiltration of adipose 
tissue by macrophages and as a result of adipocytes produce their own 
inflammatory cytokines. This inflammatory response of the adipose tissue 
is a vital step in the progression of peripheral insulin resistance. 
The numerous pathways of inflammation are found to be initiated 
by extracellular mediators or by intracellular stress, mainly oxidative 
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stress which leads to over-production of reactive oxygen species in the 
mitochondria. Signals from all of these mediators converge on 
inflammatory signalling pathways, which lead to the production of further 
mediators of inflammation through regulation of transcription regulation 
as well as to the direct inhibition of insulin signalling 61. 
Inflammatory cytokines:  
Interleukin-6: 
The pro-inflammatory cytokine interleukin-6 was among the first 
to be implicated a as predictor of insulin resistance and cardiovascular 
disease. There is an increased circulating level of interleukin-6 in 
individuals with Type-2 DM. The production of interleukin-6 by the 
abdominal adipose tissue is much higher than that from the subcutaneous 
adipose tissue. This points towards the fact that interleukin-6 may be one 
of the factors that make central adiposity a high risk factor for the 
development of insulin resistance 62.  
 
Interleukin-10:  
It is an anti-inflammatory cytokine. The decrease of its synthesis is 
found to be associated with the development of Type-2 DM. The immune 
cells in the adipose tissue are found to produce this anti-inflammatory 
factor. It acts on adipocytes to improve signalling pathways of insulin 
action and also decreasing further macrophage recruitment 63.  
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Tumour Necrosis Factor-α:  
It is a cytokine secreted both by immune cells and adipocytes. It 
has been found to play a role in the development of insulin resistance 64. 
 
Resistin:  
Resistin is an inflammatory cytokine produced by the cells in the 
adipose tissue and immune cells. Its expression is found to be suppressed 
by thiazolidinediones and is up-regulated by pro-inflammatory cytokines 
and bacterially derived lipopolysaccharide 65. It stimulates intracellular 
signalling through NF-kB activation, which in turn promotes the 
synthesis of other pro-inflammatory cytokines and surface adhesion 
molecules 66. 
 
Monocyte chemoattractant protein-1:  
It is a chemoattractant protein. Its main role is to recruit the cells of 
the immune system to inflammatory sites. Increased levels of this protein 
are implicated in onset of several diseases which are represented by the 
infiltration of monocytes such as psoriasis, rheumatoid 
arthritis and atherosclerosis67. 
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C-reactive protein:  
It is a major acute phase reactant. It is synthesised mainly in the liver. 
Levels of C-reactive protein are increased in conditions of inflammation 
and they have been established as a risk marker for cardiovascular risk. 
Its levels have been correlated with insulin resistance 68. 
Myeloperoxidase (MPO): 
Agner described the purification of an intensely green iron-
containing protein from purulent fluid in patients with tuberculous 
empyema. It was found to exhibit peroxidase activity. Because of its 
green colour, it was termed initially as verdo-peroxidase. As consequent 
studies showed that this enzyme expression was restricted to myeloid 
lineage cells, it was named MPO (EC.1.11.1.7).  Chromosome 17 hosts 
the gene that encodes this enzyme on its long arm 17q22-q23 69. 
Immediately after translation of the MPO gene, a single 80kDa 
protein is produced. This enters the endoplasmic reticulum and undergoes 
cleavage of the signal peptide which is made of 41 aminoacids. Further, 
N-linked glycosylation occurs which leads to incorporation of mannose 
rich side chains. This leads to the formation of 90kDa apo-pro-MPO. 
Apo-pro-MPO is enzymatically inactive because it lacks heme. The 
enzymatically active pro-MPO is formed by the incorporation of heme. 
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This enters the Golgi complex. It undergoes a range of post-translational 
proteolytic modifications to produce the full mature protein. The first 
proteolytic action cleaves the 125 amino acid pro-peptide to generate a 74 
kDa short lived intermediate. Then it undergoes a second cleavage to 
form two subunits which consists of a 59 kDa heavy subunit and a 13.5 
kDa light subunit. These two subunits are linked by covalent bonds with 
the associated heme group. The native form of MPO has heme in the 
ferric state. The mature MPO protein is formed by the combination of 
two heavy and light protomers. They are linked by a disulfide bond 
between the heavy subunits. The protein after complete post-translational 
modifications is a homodimer which is of 145 kDa and glycosylated. This 
homodimer form is the one found in the primary granules of neutrophils 
and monocytes 70. The polymorphonuclear neutrophilic cells contain 
azurophil granules which stores the enzyme MPO. 
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Figure 3.3: X-Ray crystallographic structure of human MPO 
 
 
 
Source: X-ray Crystal Structure and Characterization of Halide-binding 
Sites of Human Myeloperoxidase at 1.8 Å Resolution. Tristan J. Fiedler, Curt A. 
Davey, Roger E. Fenna. J. Biol. Chem. 2000, 275:11964-11971. 
 
MPO has been traditionally associated with the process of innate 
immunity. The complex reactions involved in microbial killing are found 
associated with MPO. The exceptional ability of this enzyme is to create 
hypochlorite ion which is formed by the reaction between hydrogen 
peroxide and chloride ions. The acute inflammatory reaction sets in 
causing damage to membrane lipids, proteins and nucleic acids. MPO has 
been concerned in diseases linked with chronic pathological processes, in 
which oxidative stress and inflammation play dominant roles.  
 
Two large polypeptide 
chains 
Heme 
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The enzymatic reaction catalysed by MPO is: 
 H2O2 + Cl
-                          HOCl + H2O 
Hypochlorous acid (HOCl) by further reactions interacts with 
hydrogen peroxide, nitrates to produce highly reactive oxygen and 
nitrogen species respectively. In addition, HOCl is also found to react 
with different proteins to form chloramines and modified proteins such as 
LDL which is modified by the action of HOCl 71. As these products are 
highly reactive they induce destruction of the invading pathogens and is 
almost consistently associated with some degree of harm to the host 
tissue. These reactions are primarily meant to take place within the 
limitations of the phagosomes. But occasionally, they are released outside 
the cell and this brings about destruction of bio-molecules in the adjacent 
tissue. Even if MPO is fundamental for the defence against invading 
pathogens, inefficient enzymatic activity could direct to host tissue 
damage. MPO activity is seen to be increased and being implicated in a 
wide variety of diseases. The pathological conditions associated with 
inefficient MPO activity includes the following - cardiovascular disease, 
malignancies, chronic kidney disease, lung injury and Alzheimer’s 
disease 1. 
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MPO and endothelial dysfunction:  
MPO plays an important role in the commencement, evolution and 
the complications of atherosclerosis. MPO leads to endothelial 
dysfunction by making use of the hyperglycemia stimulated H2O2 which 
is derived from vascular non-leukocyte cells by reducing nitric oxide 
bioavailability 72.  
 
Mechanisms by which MPO promotes atherosclerosis: 
A considerable number of epidemiological and clinical studies 
have demonstrated an association between increased concentrations of 
MPO and CVD, independent of classical risk factors.  
The source of MPO and subsequent formation of reactive species may be 
triggered by several mechanisms: 
1.  Inflammation induces recruitment and activation of white blood 
cells which secretes MPO. 
2.  Minimally modified LDL particles in the intima triggers the influx 
of monocytes that mature into resident macrophages, some of which 
express MPO. 
3.  Neutrophils in the blood stream are attracted and bound to sites of 
damaged endothelium. MPO released by these adherent leukocytes is 
initially bound to the vascular endothelium and subsequently transcytosed 
to the sub-endothelial matrix.  
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MPO activity leads to oxidation of LDL cholesterol, which increases its 
atherogenicity. MPO-induced oxidation of HDL cholesterol can reduce 
its capacity for reverse cholesterol transport. MPO activity leads to 
consumption of endothelial derived nitric oxide, which can lead to plaque 
formation and endothelial dysfunction 73. Moreover, MPO plays a role in 
the conversion of a stable to unstable plaque. HOCl produced by MPO 
induction promotes programmed cell death of the endothelial cell and 
detachment leading to superficial erosions.  
 
LDL oxidation by MPO:  
The oxidative modification of LDL is an early event in 
atherosclerosis. Oxidized LDL contributes to atherogenesis by promoting 
cholesterol deposition and transformation of macrophages into foam 
cells. Retention of LDL in the sub-endothelial space makes LDL a major 
site for oxidation by pro-oxidants produced by arterial cell wall. Sources 
of oxidants include NADPH oxidase, xanthine oxidase, lipooxygenases, 
mitochondrial respiration, uncoupled nitric oxide synthase and MPO. 
MPO is a protein that is strongly cationic in nature. It can bind to cells in 
the vascular endothelium, leukocytes and LDL. The association of MPO 
and LDL enhances the oxidation of this lipoprotein. MPO generates a 
number of reactive species including HOCl, chloramines, tyrosyl radicals 
and nitrogen dioxide, which oxidizes the protein, lipid and anti-oxidant 
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constituents of LDL. Many of the primary oxidation products are unstable 
and serve as reactive intermediates. This promotes further oxidative 
modification of LDL and also led to cross-linking and aggregation. The 
modified tyrosine residues, 3-nitrotyrosine and 3-chlorotyrosine, are 
among the best characterized of the stable oxidation products of MPO 73. 
In contrast to 3- nitrotyrosine, 3-chlorotyrosine is uniquely produced by 
MPO, and may therefore serve as a unique molecular fingerprint for MPO 
catalyzed oxidation. The concentration of 3- chlorotyrosine in LDL 
secluded from atherosclerotic intima was many folds high in circulating 
LDL 74. 
 
Impairment of HDL functions by MPO: 
In addition to playing a central role in cholesterol efflux and 
reverse-cholesterol transport, HDL also possesses anti-inflammatory and 
anti-oxidative properties. HDL can prevent or delay oxidation in the 
vessel wall. In metabolic diseases associated with accelerated 
atherosclerosis as in DM, HDL particles become functionally defective. 
Dysfunctional HDL particles lack athero-protective properties and 
promote pro-inflammatory effects. MPO is implicated in rendering HDL 
dysfunctional. MPO mediated oxidation of HDL occurs preferentially at 
the apo A-1 in the HDL molecule. This is evident from the fact that there 
is a hundred fold increase of both 3-nitrotyrosine and 3- chlorotyrosine in 
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apo A-1 isolated from circulating HDL in comparison with other 
circulatory proteins. Selective targeting of apo A-1 is explained by the 
fact that apo A-1 contains an exact binding site for MPO 75. Importantly, 
HDL bound MPO retain its enzymatic activity and binding to HDL 
protects MPO from cellular uptake and degradation. The HDL which is 
modified by MPO dependent reactions profoundly increases the affinity 
of HDL to bind to MPO, which has been projected to lead to a vicious 
sequence of modifications mediated by MPO at sites of chronic 
inflammation. 
Figure 3.4: Functions of HDL 
  
 
Abbreviation: NO-Nitric oxide, LPS- Lipopolysaccharide 
LDL particles penetrate the intimal layer of the arteries where it may 
undergo minimal modifications by reactive oxygen species. This 
consequently leads to the induction of monocytes to migrate into the 
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vessel wall. They undergo differentiation into macrophages. In the 
macrophages, scavenger receptors recognise the modified oxidized LDL 
and leads to its uptake. The excess uptake of the modified LDL leads to 
formation of foam cell. During conditions of inflammation, MPO gets 
released by macrophages and catalyzes the production of reactive species 
using different substrates such as chloride, thiocyanate or nitric oxide 
with H2O2 as co-substrate. This results in depletion of nitric oxide which 
leads to an impairment in vasodilatation. The reactive species formed can 
also oxidize LDL particles to form oxidized LDL, renders HDL to lose its 
functions by enhancing the formation of oxidized HDL, which impairs 
the protective effect of HDL on LDL-particles and in addition inhibiting 
reverse-cholesterol transport. 
 
MPO reduces bioavailability of nitric oxide:  
 In the endothelium, synthesis of nitric oxide by the endothelial 
isoform of nitric oxide synthase helps in the regulation of blood vessel 
tone. The nitric oxide produced acts as a powerful vasodilator. In addition 
it is found to suppress the endothelial binding of cells in the circulation. It 
also inhibits smooth muscle cell proliferation in the vessel wall. These 
actions point towards the fact that nitric oxide is an essential element for 
the maintenance of vascular homeostasis. There is an increase in the rate 
of atherosclerosis and impairment of vascular functions due to inadequate 
58 
production or increased removal of nitric oxide. MPO is found to reduce 
the bioavailability of nitric oxide by a number of mechanisms. One 
proposed mechanism is that peroxidases can also use nitric oxide as a 
substrate and thus one of the members of the peroxidase family namely 
MPO serves as a catalytic sink for nitric oxide 76. Second, reactive 
substances produced by MPO leads to the removal of nitric oxide which 
further reduce its bioavailability. One other mechanism suggests that 
hypochlorous acid reacts with arginine, one of the nitric oxide synthase 
substrate and forms chlorinated arginine compounds. These compounds 
are inhibitors of all isoforms of the nitric oxide synthase enzyme thus lead 
to impaired endothelium-dependent relaxation 77. Finally, it has been 
established that nitric oxide synthase uncoupling is induced by 
hypochlorous acid. This turns it into a superoxide-producing enzyme. 
Even though the relative impact of these mechanisms is currently 
indefinite, it is clear that MPO is found to deplete nitric oxide in the 
endothelial vessel walls by both catalytic as well as non-catalytic 
mechanisms. 
 
MPO and plaque vulnerability:  
Acute cardiovascular events are found to be induced by the crucial 
processes such as destabilization of the atherosclerotic plaque and 
rupture. MPO activates the metalloproteinases which thereby leads to 
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weakening of the fibrous cap of the plaque, thus leading to its 
destabilization. Plaque injury activates neutrophils, which leads to MPO 
release. Malle et al 78 observed co-localization of MPO and hypochlorite 
customized proteins in lesions of human atherosclerotic plaque. 
Sugiyama et al 79 reported that there was little or no MPO in macrophages 
isolated from fatty streaks of the atherosclerotic plaque whereas 
macrophages in plaques that undergo erosions and rupture are rich in 
MPO. 
Figure 3.5: Adverse effects of MPO in the vasculature 
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Importance of MPO in DM: 
 
Inflammation has been recognized as the underlying basis of 
chronic diseases including Type-2 DM. It has a fundamental role in 
mediating all the phases of atherosclerosis, from the commencement 
stage through progression and ultimately leading to thrombotic 
complications.  
 
In Type-2 diabetes, inflammation and activation of monocytes play 
a predominant role in reducing insulin sensitivity and also contributes to 
the loss of insulin secretion by islet cells. Hyperglycemia associated with 
diabetes can lead to alterations in the macromolecules which forms AGE 
and others, which can enhance the formation of pro-inflammatory 
markers like cytokines in vascular endothelium.  
 
Free radicals are formed excessively in diabetes. This excess 
production has been attributed to oxidation of glucose, glycation of 
proteins and oxidative breakdown of glycated proteins. The raised levels 
of reactive oxygen species and associated reduction of antioxidant 
defence mechanisms leads to cellular damage. It also leads to an increase 
in the propensity for lipid peroxidation and development of insulin 
resistance. Inflammation and oxidative stress can accelerate the process 
of atherosclerosis in DM. MPO, a pro-oxidant enzyme, released from the 
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granules of leukocytes, monocytes and macrophages from the 
inflammatory sites can stimulate increased production of reactive oxygen 
species which can cause oxidative damage to the endothelium and vessel 
wall. Cardiovascular disease accounts for about 70% of all deaths in 
patients with diabetes. This increase has been ascribed to accelerated 
atherosclerosis and endothelial dysfunction which are due to the 
inflammatory and oxidative stress response in diabetic patients. 
 
Evidence regarding MPO activity in diabetes is limited and 
inconsistent, demonstrating both higher and lower levels of MPO in 
different tissues and clinical situations 80, 81, 82. However, it is known that 
endothelial dysfunction develops early in DM, preceding clinically 
detectable atherosclerosis, and that diminished nitric oxide levels and 
enhanced oxidative stress are important determinants in the pathogenesis 
of diabetic vascular complications. Type-2 DM is associated with mildly 
increased levels of MPO, independent of other clinical considerations.  
 
This relationship may add-up to the accelerated progression of 
atherosclerosis in diabetes. MPO plays an important role in the initiation, 
progression and the rupture of plaque seen in atherosclerosis. Previous 
studies have specifically focused on the relation between MPO levels and 
the presence of endothelial dysfunction in diabetes.  
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These studies showed a significantly higher MPO levels in 
diabetes. But some studies also showed no correlation of MPO level in 
diabetes 83. Not many works are there to see the relationship between 
MPO and HbA1c and also with lipid abnormalities. So this study is 
undertaken to see the plasma MPO activity, lipid profile and HbA1c and 
also to see the relationship between them. 
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MATERIALS AND METHODS 
 
The study was conducted for a period of one year at PSG Institute 
of Medical Sciences and Research, Coimbatore. An informed consent 
was taken from the patients before sample collection. Ethical clearance 
was obtained from the Institutional Human Ethics Committee.  
 
It is a cross-sectional study including two groups. Non-diabetic 
healthy individuals served as controls (n=50). The cases included patients 
diagnosed with type-2 DM satisfying the inclusion and exclusion criteria. 
(n=50). Cases were selected from diabetic patients attending 
Endocrinology and Medicine OPD. Non-diabetic controls were included 
from those attending the master health check-up. The patients recruited in 
the study were randomly selected.  
Inclusion criteria: 
1)  Age>30 years 
2)  Patients diagnosed as type 2 DM as per WHO criteria not less than  
one year duration 
Exclusion Criteria: 
1)  Chronic kidney disease. 
2)  Coronary artery disease.  
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3)  Previous vascular disease. 
4)  Auto-immune disease. 
5)  Hypertension. 
6)  Patients on treatment with statins. 
Collection of blood samples: 
5 ml of venous blood sample was collected after a period of 12 
hours overnight fasting HbA1c, lipid profile and plasma MPO activity 
were estimated in the sample. 
Anthropometric measurements like weight and height were also 
recorded. 
 
PLASMA MPO ACTIVITY: 
Method: 
Serum MPO was estimated by spectrophotometric method using 
O-dianisidine dihydrochloride as a substrate 84.  
 
Principle: 
This method is based on the oxidation of O-dianisidine (colourless 
chromogen) by hydrogen peroxide to form a yellowish orange coloured 
oxidized product. 
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         MPO    
O-dianisidine + H2O2                          Oxidized O-dianisidine (Yellowish orange  
                  Coloured product) + H2O 
The increase in absorbance at 470nm due to the formation of oxidised o-
dianisidine was measured. 
 
Reagents: 
All the chemicals were of analytical grade. 
1.  Stock phosphate buffer: Consist of solution A and solution B 
Solution A – 1M Dipotassium hydrogen phosphate solution. Prepared by     
mixing 17.41g  K2HPO4 in 100 mL distilled water. 
Solution B – 1M Potassium dihydrogen phosphate solution. Prepared by  
mixing 13.6g  KH2PO4 in 100 mL of distilled water. 
2.  Working phosphate buffer: Prepared by mixing 13.2mL of solution 
A with 86.8mL of solution B and made up to 500mL with distilled 
water. The pH of the working buffer was maintained at 6. 
3.  Substrate: O-Dianisidine Dihydrochloride (5mg/L). Substrate must 
be freshly prepared by mixing 5mg of O-Dianisidine 
dihydrochloride (Sigma-Aldrich product) in 1mL of distilled water. 
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4.  HydrogenPeroxide: 30% Hydrogen peroxide solution was used 
directly. 
Procedure: 
• 2.8mL of working buffer was taken in a test tube.  
• To this 0.1ml O-Dianisidine dihydrochloride (5mg/mL) was added. 
• To this solution 25 µL of sample was added. 
• The solution was taken in a cuvette. 
• Spectrophotometer was set at 470nm and calibrated with distilled 
water as blank. 
• 100 µL of Hydrogen peroxide was added to the reacting mixture in 
the cuvette and kept in spectrophotometer.   
• Optical density was measured at 30 second intervals for 2 minutes. 
Calculation: 
One unit (U) of MPO activity was defined as that degrading 1 µmol 
of hydrogen peroxide per minute at 250C. 
 
Activity of MPO in the given sample =   ∆OD/minute x 3.025  
                  0.025 x 11300 x 106 
           =   ∆OD/minute × 10676 U/L 
Where ∆OD = (Final optical density – initial optical density)/2 
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3.025 is reaction volume in mL 
0.025 is the sample volume in mL 
11300 is the molar absorptivity in Mol/cm 
PLASMA GLUCOSE 
Method: 
Enzymatic reference method with hexokinase. 
Principle: 
The phosphorylation of glucose by ATP to form glucose-6 
phosphate and ADP is catalysed by Hexokinase (HK). This is followed 
by the action of another enzyme, glucose-6 phosphate dehydrogenase 
(G6PDH). This enzyme catalyzes oxidation of glucose-6 phosphate by 
NAD+ to form NADH. 
 
Reaction: 
       HK 
D-glucose + ATP                   D-glucose-6 phosphate + ADP 
 
 
        G6PDH 
D-glucose-6 phosphate + NAD+                          D-6 phosphogluconate 
         +NADH+H+ 
 
68 
The concentration of NADH formed is directly proportional to the 
glucose concentration. It is determined by measuring the increase in 
absorbance at 340nm. 
Test definition: 
Mode of measurement Absorbance 
Mode of calculation of absorbance Endpoint 
Mode of reaction R-S 
Direction of Reaction Increase 
Wavelength A/B 340/409 nm 
Test range 0-40 mmol/L (0-720 mg/dL) 
Unit mmol/L 
 
SERUM TOTAL CHOLESTEROL 
Method: 
Enzymatic colorimetric test. 
The method involves use of enzymes cholesterol esterase, cholesterol 
oxidase and peroxidase. 
 
Principle: 
Cholesterol esters are cleaved by the action of cholesterol esterase 
(CE) to yield free cholesterol and fatty acids. Cholesterol oxidase 
(CHOD) in a second reaction catalyzes the oxidation of cholesterol to 
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cholest-4-en-3-one and hydrogen peroxide. In the presence of peroxidase 
(POD), the hydrogen peroxide formed effects the oxidative coupling of 
phenol and 4-aminoantipyrine to form a red quinone-imine dye.  
Reaction: 
     CE 
Cholesterol esters + H2O                           Cholesterol + R-COOH 
    CHOD 
Cholesterol + O2                                Cholest-4-ens-3-one + H2O2 
         POD 
2 H2O2 + 4 AAP + Phenol                                Quinone-imine dye + H2O 
 
The color intensity of the dye formed is directly proportional to the 
cholesterol concentration. It is determined by measuring the increase in 
absorbance at 512 nm. 
Test definition: 
Mode of measurement Absorbance 
Mode of calculation of absorbance Endpoint 
Mode of reaction R-S 
Direction of Reaction Increase 
Wavelength A/B 512/659 nm 
Test range 0-20.7 mmol/L (0-800 mg/dL) 
Unit mmol/L 
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SERUM TRIGLYCERIDES: 
Method: 
Enzymatic, colorimetric method. 
Involves enzymes glycerol  phosphate  oxidase  and   4-aminophenazone. 
Principle: 
Lipoprotein lipase (LPL) hydrolyzes the triglycerides to glycerol 
and fatty acids. Glycerol is phosphorylated to glycerol-3-phosphate by 
ATP catalyzed by glycerol kinase (GK). The oxidation of glycerol-3-
phosphate is catalyzed by glycerol phosphate oxidase (GPO) to form 
dihydroxyacetone phosphate and hydrogen peroxide. In the presence of 
peroxidase (POD), hydrogen peroxide effects the oxidative coupling of 4-
chlorophenol and 4-aminophenazone to form a red-coloured 
quinoneimine dye, which is measured at 512 nm. The increase in 
absorbance is directly proportional to the concentration of triglycerides in 
the sample. 
 
Reaction: 
         LPL 
Triglycerides                                           Glycerol + Fatty acids 
         GK 
Glycerol + ATP                             Glycerol-3 phosphate + ADP 
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                         GPO 
Glycerol -3 phosphate +  O2    Dihydroxy acetone  
      Phosphate+H2O2 
            POD 
2 H2O2 + 4 aminophenazone  Quinoneimine dye  
             +4H2O+4Chlorophenol 
Test definition: 
Mode of measurement Absorbance 
Mode of calculation of absorbance Endpoint 
Mode of reaction R-S 
Direction of Reaction Increase 
Wavelength A/B 512/659 nm 
Test range 0-10 mmol/L (0-885 mg/dL) 
Unit mmol/L 
 
SERUM HDL CHOLESTEROL: 
Method: 
Homogenous enzymatic colorimetric assay. 
Principle: 
In the presence of magnesium ions, dextran sulphate selectively 
forms water-soluble complexes with LDL, VLDL and chylomicrons 
which are resistant to PEG modified enzymes. The cholesterol 
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concentration is initially determined by enzymatic methods using 
cholesterol esterase and cholesterol oxidase coupled with PEG to the 
amino groups. Cholesterol esterase breaks down the cholesterol esters 
into free cholesterol and fatty acids. The enzyme cholesterol oxidase 
oxidizes the cholesterol in the presence of oxygen to ∆4-cholestenone and 
hydrogen peroxide. In the presence of peroxidase, the hydrogen peroxide 
generated reacts with 4-aminoantipyrine and HSDA to form a purple-blue 
dye. The intensity of colorformed by the blue quinoneimine dye formed is 
directly proportional to the cholesterol concentration which is measured 
photometrically. 
Reaction: 
       PEG cholesterol esterase 
HDL Cholesterol ester + H2O                               HDL Cholesterol + 
                                                      RCOOH 
                                  PEG Cholesterol oxidase 
HDL-Cholesterol +O2                                               4-cholestenone + H2O2 
            POD 
2H2O2 + 4 aminoantipyrine + HSDA+H
+                     Purple blue  
         Pigment+4H2O 
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Test definition: 
Mode of measurement Absorbance 
Mode of calculation of absorbance Endpoint 
Mode of reaction R1-S-SR 
Direction of Reaction Increase 
Wavelength A/B 583/659 nm 
Test range 0-3.12 mmol/L (0-120 mg/dL) 
Unit mmol/L 
 
SERUM LDL CHOLESTEROL: 
Method: 
Homogeneous enzymatic colorimetric assay. 
Principle: 
This method is based on the property of selective micellary 
solubilization of LDL-cholesterol by a non-ionic detergent. It also utilises 
the interaction of a sugar compound with lipoproteins such as VLDL and 
chylomicrons. Addition of a detergent to the enzymes used for cholesterol 
estimation (cholesterol esterase - cholesterol oxidase coupling reaction), 
increases the relative reactivities of cholesterol in the lipoprotein fractions 
in the following order: HDL < chylomicrons < VLDL < LDL. The 
activity of the enzymes used in the cholesterol estimation is reduced in 
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the presence of magnesium ions and a sugar. The selective estimation of 
LDL-cholesterol in serum is enabled by the reaction of a sugar molecule 
with a detergent. In the presence of oxygen, cholesterol is oxidized by 
cholesterol oxidase to ∆4-cholestenone and hydrogen peroxide. The 
intensity of the blue quinoneimine dye formed is directly proportional to 
the concentration of LDL cholesterol. It is determined by monitoring the 
increase in absorbance at 583 nm. 
Reaction: 
   Detergent cholesterol esterase 
LDL-Cholesterol ester + H2O                       Cholesterol + Free fatty acid 
     (Selective micellary solubilisation) 
  Cholesterol oxidase 
LDL-Cholesterol + O2                              ∆4-cholestenone + H2O2 
2H2O2 + 4 aminoantipyrine + HSDA+H
+                    Purple blue  
            pigment+4H2O 
Test definition: 
Mode of measurement Absorbance 
Mode of calculation of absorbance Endpoint 
Mode of reaction R1-S-SR 
Direction of Reaction Increase 
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Wavelength A/B 583/659 nm 
Test range 0-14.2 mmol/L ( 0-550 mg/dL) 
Unit mmol/L 
 
Glycated haemoglobin: (HbA1c) 
Method:  
Turbidimetric inhibition immunoassay  
Principle: 
EDTA tube collected whole blood specimen is hemolysed after 
collection. Total hemoglobin and HbA1c concentrations are determined. 
Total hemoglobin is measured colorimetrically. The percentage of HbA1c 
is determined immunoturbidimetrically. The ratio of both these levels 
gives the final percent HbA1c result. 
 
EDTA collected blood is hemolysed with hemolysis reagent in the 
predilution cuvette. This leads to reduction in osmotic pressure which 
lyses the erythrocytes. Lysis of erythrocytes releases the haemoglobin. It 
is degraded by the proteolytic action of the enzyme pepsin. This renders 
the beta-N terminal structures more available for the immunoassay.  
In the hemolysate, a colorimetric method helps in the determination 
of total haemoglobin. This is done on the basis of production of a 
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brownish-green chromophore. This occurs in alkaline detergent solution 
using a cyanide free method. 
 The intensity of colour is directly proportional to the total 
hemoglobin concentration in the sample. The concentration is determined 
by sensing the increase in absorbance at 552nm. A fixed factor that is 
obtained from the primary calibrator chlorohemin calculates the test 
results. 
Turbidimetric method to measure HbA1c is done using monoclonal 
antibodies which are present attached to latex particles. The monoclonal 
antibodies bind the amino terminal fragments of HbA1c. The unbound 
free antibodies agglutinate with an artificial polymer. The change in 
turbidity is inversely related to the quantity of bound glycated proteins. 
This is measured turbidimetrically at 552nm. 
 
The final result is expressed as percentage HbA1c. It is calculated 
from the ratio of HbA1c/Hb as given below: 
According to IFCC 
HbA1c (%) = ( HbA1c / Hb) x 100 
According to DCCT/NGSP 
HbA1c(%) = (HbA1c/Hb) x 87.6 + 2.27 
 
 
77 
Test definition: 
Mode of measurement Absorbance 
Mode of calculation of absorbance Endpoint 
Mode of reaction D-R1-S-SR 
Direction of Reaction Increase 
Wavelength A/B 552nm 
Test range 1.4-4.7µmol/L (2.4-75.8mg/dL) 
Unit µmol/L 
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STATISTICAL ANALYSIS 
Baseline characteristics are measured as Mean ± SD. Significance 
is assessed at 5% level of significance. Student‘t’ test (two tailed, 
independent) and Chi-square test has been used to find the significance of 
study parameters. ROC curve analysis is performed to find the sensitivity 
and specificity of the diagnostic test. Pearson correlation was done to 
establish correlation between MPO and other relevant parameters such as 
lipid profile and HbA1c. 
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RESULTS 
This study was done to estimate the plasma MPO levels in patients 
with type-2 DM and to compare the same with healthy non-diabetic 
control patients. In addition, plasma MPO activity was correlated with 
lipid profile and HbA1c. 
 
 
AGE DISTRIBUTION OF THE STUDY POPULATION: 
Table 6.1: Distribution of cases and controls as per age group. 
Age  
Controls Cases 
Number Percent Number Percent 
31-40 yrs 11 22.0 11 22 
41-50 yrs 19 38.0 14 28 
51-60 yrs 15 30.0 14 28 
>60 yrs 5 10.0 11 22 
 
 
 
 
 Figure 6.1: Age distribution of the study 
 
The age distribution of control subjects and 
shown in the Figure
mean age of diabetic cases and controls.
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Table 6.2:  Mean Age of Study Population 
 
Age in years 
Controls Cases 
Mean ±SD 48.12±8.56 51.30±11.41 
p value          0.16 (Not significant)  
 
 
 
Table 6.3: Gender Distribution of Study Population: 
 
  Controls Cases 
Number of males 29 33 
Number of females 21 17 
 Total 50 50 
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Figure 6.2: Gender distribution in control group 
 
 
Figure 6.3: Gender distribution in diabetic patients group 
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BMI in the study population
 of study groups 
Body mass index  (kg/m2) 
Controls Cases 
 26.41±4.40 27.06±4.79
 0.48(Not significant) 
2) in non-diabetic controls is about 26.41 ± 
18.5-24.9 25.0-29.9 >=30
BMI (kg/m2)
 
 
 
Controls
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BMI between the study groups is not statistically significant 
0.48). 
Figure 6.5: Fasting blood sugar
The distribution of the fasting blood sugar concentrations in both 
the study groups is presented graphically in Fig
glucose levels in the control g
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Table 6.5: Comparison of lipid profile between the study groups 
  
Controls Cases p value 
             Mean ± SD 
Serum cholesterol (mg/dL) 182.2± 36.86 189.70±35.24 0.3 
Serum triglycerides (mg/dL) 128.38±53.19 164.16±90.55 0.02* 
Serum HDL (mg/dL) 45.02±13.17 43.00±9.73 0.39 
Serum LDL (mg/dL) 124.18±13.17 120.4±31.00 0.5 
*p <0.05 – Statistically significant 
The mean of the lipid profile of cases and controls are compared in 
Table 6.5. There was statistically significant difference in the triglyceride 
levels of the diabetic cases when compared with the non-diabetic 
controls. The other parameters of the lipid profile did not differ 
significantly between the two study groups. 
Table 6.6: Plasma MPO activity in cases and controls. 
PLASMA MPO ACTIVITY (U/L) 
  Controls Cases 
Mean ± SD 188.41±142.73 317.17±247.73 
p value 0.0019* 
*p <0.05 – Statistically significant 
 
Figure 6.6: MPO activity in the study population
 
Plasma MPO activity in diabetics is significantly higher than in the 
controls with p value of 0.0019 (p <0.05 
mean MPO activity in 
that none of the diabetic patients had MPO activity of less than 100 U/L.
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Figure 6.7: MPO activity vs BMI in controls
Figure 6.8: MPO activity vs BMI in cases 
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In the control group, MPO activity is found to increase with 
increase in Body mass index. MPO activity of >400U/L is highest in the 
individuals with BMI≥30kg/m2 as shown in Figure 6.7  
             Increased MPO activity of >400U/L is found to increase with an 
increase in BMI.  
 Plasma MPO activity with respect to gender is analysed and 
presented in the following figures. 
Figure 6.9: MPO activity vs gender in controls  
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Figure 6.10: MPO activity vs gender in cases  
 
  
Though MPO activity is found to be higher in males when 
compared to females in the two groups as shown in Figure 6.9 and Figure 
6.10, there is no significant statistical difference in MPO activity in both 
the genders in the study population (p value of 0.19 in control group and 
0.38 in cases group) 
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Correlational analysis between MPO activity and BMI (expressed 
as kilograms/metresquare), serum cholesterol (expressed as mg/dL), 
serum triglyceride (expressed as mg/dL), serum HDL (expressed as 
mg/dL), HbA1c (measured as %) in the diabetic patients is done using 
Pearson’s correlational testing and the results are presented in Table 6.7. 
 
Table 6.7: Pearson’s correlation analysis between MPO activity and 
BMI, Serum Cholesterol, Serum Triglycerides, Serum HDL, HbA1c 
in cases 
  r value p value 
MPO activity & BMI 0.154 0.286 
MPO activity  & Serum Cholesterol 0.272 0.056 
MPO activity  & Serum HDL -0.091 0.345 
MPO activity & Serum Triglycerides 0.437 0.002* 
MPO activity & HbA1c 0.235 0.1 
*p <0.05 – Statistically significant 
 
The Pearson correlation of MPO activity with total cholesterol, 
triglyceride, BMI and HbA1c is shown in Table 6.7. In the present study, 
a significant positive correlation is observed between MPO activity and 
serum triglyceride levels. The correlation of MPO activity with BMI, 
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Cholesterol and HbA1c is not very relevant. The moderate correlation 
between plasma MPO activity and serum triglyceride levels are 
represented in the scatter diagram Figure 6.11. 
 
Figure 6.11: Scatter plot showing the correlation between triglyceride 
levels and MPO activity  
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Further ROC curve has been used to find sensitivity and specificity 
of serum MPO activity in diabetic patients. This curve is compared with 
ROC curves for serum triglyceride levels, serum HDL levels and serum 
LDL levels. (Figure 6.12) The area under the curve for each of these 
parameters is presented in Table 6.8. 
 
Figure 6.12: Comparison of ROC curves of MPO activity, serum 
triglycerides, serum HDL, serum LDL 
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Table 6.8: Comparison of area under the curves for different 
parameters: 
Variable Area Significance 
Triglyceride 0.635 0.02* 
HDL 0.455 0.436 
LDL 0.442 0.319 
MPO 0.696 0.001* 
 
*p <0.05 – Statistically significant 
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DISCUSSION 
Diabetes mellitus is characterised by chronic hyperglycemia due to 
relative insulin deficiency or insulin resistance or both. Chronic 
hyperglycemia is the primary etiological factor for the development of 
vascular complications of DM.  
 
DM is associated with low-grade inflammation and amplified 
endothelial dysfunction. Persistent hyperglycemia in diabetes can 
aggravate inflammation and lead to increased production of reactive 
oxygen species from glucose auto-oxidation which can predispose to 
harmful consequences in diabetic patients. Endothelial dysfunction is a 
major contributing factor to the pathogenesis of diabetic vascular 
complications. ROS such as superoxide ions and hydrogen peroxide have 
emerged as important molecules in the pathogenesis of diabetic vascular 
complications, including endothelial dysfunction. Vascular NADPH 
oxidase, the non-leukocyte oxidase, has proven to be the major source of 
ROS in diabetic vasculature 73. Increased levels of MPO activity 
contribute to initiation and accelerated progression of atherosclerosis in 
diabetes 85. MPO can use high-glucose stimulated, vascular non-
leukocyte derived hydrogen peroxide to induce diabetic endothelial 
dysfunction by reducing nitric oxide bioavailability 86. 
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In the present study, plasma MPO levels are significantly higher in 
the diabetic patients as compared to the non-diabetic controls (p <0.05). 
This finding is consistent with the study by Wiersma et al 85 in which 
there was significant increase in the myeloperoxidase levels in diabetic 
patients. DM is considered to be a state of low grade and chronic 
inflammation. It has been also associated with accelerated atherosclerosis 
which predisposes these individuals to risk of cardiovascular disease. 
MPO-catalyzed reactions have been attributed to potentially pro-
atherogenic biological activities throughout the evolution of 
cardiovascular disease, including initiation, propagation and acute 
complication phases of the stages of atherosclerosis 2. This explains the 
increase in MPO activity in diabetic patients. 
 
The mean fasting blood glucose concentrations is much higher in 
the plasma of the diabetic group (204.14 ± 75.64mg/dL). This increased 
glucotoxicitycan contribute to oxidative stress and increased 
inflammation which consequently results in increase in MPO activity in 
these patients. MPO can use high glucose stimulated hydrogen peroxide 
to amplify the toxic effects of increased glucose to the vascular wall 86. 
MPO activity did not significantly differ with gender in both control 
group and diabetic group as depicted in Figures 6.9 & 6.10.  
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Plasma MPO activity in both the groups is found to increase with 
an increase in body mass index. MPO activity of  > 400 U/L is more in 
the controls and cases with body mass index of  ≥  30 kg/m2 as evidenced 
in Figures 6.7 & 6.8. Obesity was found to contribute to inflammation 
by up-regulating genetic elements involved in the inflammatory response. 
These genes control the expression of leucocytes called macrophages that 
play a key role in inflammation. As the concentration of macrophages in 
the fat tissue increases, the release of inflammatory by-products such as 
interleukins and others also increase.MPO is one of the inflammatory 
mediators which has been found to be increase in obese pre-pubertal 
children and served as a marker for cardiovascular disease in these 
children 87.  
 
There is significant difference in the serum triglyceride levels in 
the two study groups (p value 0.02). DM is associated with clustering of 
lipid and lipoprotein abnormalities. One important dyslipidemia in these 
individuals which is an independent risk factor for cardiovascular 
complications is elevated triglyceride levels. This has been attributed to 
the increased hepatic secretion of triglyceride rich VLDL and impaired 
clearance of VLDL from the circulation of diabetic patients 88. There is 
no significant difference between the two groups in relation to other 
parameters of lipid profile. 
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Furthermore, Pearson’s correlation analysis done to establish 
correlation between plasma MPO activity and parameters such as BMI, 
serum cholesterol, serum triglyceride, serum HDL, HbA1c. It revealed a 
positive moderate correlation (r value of 0.4) between serum triglyceride 
levels and plasma MPO activity in diabetic patients. Although elevated 
LDL cholesterol is well established as a major predictor of coronary heart 
disease risk and has been the primary target for lipid-lowering strategies, 
evidence suggests that an elevated triglyceride level is also an 
independent risk factor 89. Hypertriglyceridemia as a result of insulin 
resistance is a consequence of enhanced breakdown of lipids in the cells 
ofthe adipose tissue.  
 
This results in flux of free fatty acid to the liver and increased 
secretion of VLDL. The increased triglyceride from VLDL further 
activates cholesterol ester transfer protein, which results in triglyceride 
enrichment of LDL and HDL. The triglyceride content within these 
particles is hydrolysed by lipases, which leads to formation of small, 
dense LDL and HDL particles. Such modified HDL becomes less 
functional. Modified small and dense LDL particles are more susceptible 
to modifications by oxidation. These modifications in the lipoproteins 
contribute to the pathogenesis of atherosclerosis 89. These modifications 
in the lipoproteins can lead to atherosclerotic changes in the vessel wall 
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which contributes to the vascular complications of diabetes mellitus. In 
our study, the correlation between serum triglyceride levels and plasma 
MPO activity shows that these patients are more prone to cardiovascular 
disease than the healthy controls.  
 
There is a weak inverse correlation between HDL levels and MPO 
activity (r value of -0.1). MPO has been found to impair the functions of 
HDL because of its capacity to convert anti-inflammatory HDL to pro-
inflammatory HDL, thereby influencing endothelial dysfunction 3. 
However there was no much significant effect on the serum HDL 
concentration in the present study. It has been demonstrated that the 
endothelial-vasoprotective effects of HDL are impaired in type 2 diabetic 
patients. The loss in beneficial functions of HDL in diabetic patient could 
be explained by the observed lipid peroxidation and increased MPO 
activity in diabetic patients. MPO has been shown to modify HDL and its 
capacity of reverse cholesterol transport 3.   
 
There is mild significant correlation between MPO activity and 
serum cholesterol levels in diabetic patients. Increase cholesterol in the 
circulation gets deposited in the walls of the arteries which leads to the 
formation of foam cells and initiates the process of atherosclerosis. The 
correlation between MPO activity and serum cholesterol levels shows the 
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efficiency of MPO as a risk indicator for predicting cardiovascular 
dysfunction in diabetic patients. 
In this study, there is mild positive correlation between HbA1c 
levels and MPO activity in the diabetic patients (r value of 0.235). Large 
volume of data from various populations has established high HbA1C 
level related with a rise in the occurrence of complications associated 
with DM. Glycated proteins lose their functional capacity and contribute 
to tissue damage and increased oxidative stress which contributes to 
vascular complications of diabetes mellitus 18. 
The rise in MPO activity is irrespective of the duration of diabetes. 
Though increase in the duration of diabetes had been associated with 
increased glucotoxicity which contributes to vascular morbidity, in our 
study there was no significant effect of the duration of diabetes on MPO 
activity.ROC curve for MPO activity had an area under the curve of 
0.696. When compared with ROC curves for serum triglycerides, serum 
HDL, serum LDL it was found that MPO activity followed by 
triglyceride levels had a larger area under the curve than serum HDL and 
serum LDL. This suggests the fact that plasma MPO activity and serum 
triglyceride levels should be given more emphasis in the clinical setting 
along with serum HDL and serum LDL levels. Increase in serum 
triglyceride levels are an independent cardiovascular morbidity and 
mortality predictor in diabetic patients 89. 
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CONCLUSION 
  
DM is an inflammatory condition which is characterised by chronic 
hyperglycemia. The increased glucose levels leads to the development of 
vascular complications in DM. Several markers have been established to 
identify the vascular disturbances in these patients at an earlier stage. 
MPO has been concerned in the development of all phases of 
atherosclerotic development by promoting LDL oxidation, producing 
dysfunctional HDL and reducing nitric oxide bioavailability. 
 
In the present study 
 
 Plasma MPO activity was significantly higher in the diabetic 
patients when compared with non-diabetic controls. 
 
 There is significantly good positive correlation between MPO 
activity and serum triglyceride levels. 
 
 ROC analysis was performed. The areas under the curve for MPO 
activity and lipid profile parameters shows that MPO activity is a 
better significant marker followed by serum triglyceride levels. 
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Inflammatory response may have a dual role in DM, either it can 
have a causal relationship leading to insulin resistance or lead to the 
series of events which progresses to atherosclerosis ensuing in vascular 
complications.  
 
In conclusion, inflammatory pathways   play   an   essential   role   
in   the   progress and evolution of vascular complications in DM. 
Modulation of inflammatory processes in diabetes by therapeutic 
intervention will have beneficial actions on patients with DM. 
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SUMMARY 
 
Myeloperoxidase, a heme peroxidase is a lysosomal protein 
released from the azurophil granules of the neutrophils. It is found to be 
an integral part of the innate immune response, by catalysing the 
formation of numerous reactive oxygen species. The products derived 
from MPO-catalyzed reactions have been ascribed to several pro-
atherogenic biological activities throughout the advancement of 
cardiovascular disease. It has been implicated in all stages of 
atherosclerotic process including initiation, propagation, and acute 
complication phases. 
 
Diabetes mellitus, a multisystem disorder is a common and 
growing public health problem. The role of endothelial dysfunction in the 
causation of vascular disease in diabetes mellitus has gained increasing 
attention. In diabetes mellitus, there is also an accelerated rate of the 
atherosclerotic process which further contributes to the vascular 
complications. Cardiovascular disease is found to be more common in the 
diabetic population than non-diabetic individuals. 
 
 This study was conducted to estimate the plasma MPO activity in 
diabetic individuals and compare them with that of non-diabetic healthy 
controls. Further the study also sought to establish any correlation 
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between plasma MPO activity and lipid profile parameters and also with 
that of HbA1c. 
 
The study involved two groups of subjects namely, healthy non-
diabetic controls and diabetic patients, 50 in each group. Plasma MPO 
activity was estimated in the study population spectrophotometrically 
using o-dianisidine as the substrate and the results were expressed in U/L. 
The lipid profile parameters such as serum total cholesterol, serum 
triglyceride, serum HDL and serum LDL were analysed in auto-analyser. 
It was found that plasma MPO activity was higher in the diabetic patients 
(317.17±247.73 U/L) when compared to healthy controls 
(188.41±142.73U/L). This difference was statistically significant. A 
positive correlation that was statistically significant was observed 
between plasma MPO activity and serum triglyceride levels in the 
diabetic patients. 
 
The increase in MPO activity in diabetic patients could be 
attributed to the hyperglycemia induced oxidative stress, inflammation 
and also the increased propensity of the diabetic individuals to 
atherosclerotic process. MPO and associated inflammatory pathways 
signify striking targets for both predictive and beneficial involvement in 
the prevention of atherosclerotic cardiovascular disease. 
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SCOPE FOR FUTURE STUDY 
 
The study needs to be carried out on larger population size along 
with more sensitive markers of inflammation to make sense of their exact 
role in the onset and progression of DM. The question whether MPO is a 
marker of an increased inflammatory state and leukocyte count in diabetic 
patients or whether MPO plays an independent role in diabetic associated 
accelerated atherosclerosis cannot be answered in this study. 
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DATA COLLECTION TOOL 
 
1. Patient’s Name : 
2. Patient’s ID  : 
3. Age   :                         
4. Sex   : 
5. Height   : 
6. Weight   : 
7. Patient’s History : 
7.1. Diabetes      : 1.Yes   2.No 
7.2. Duration of Diabetes    : 
7.3. Hypertension     : 1.Yes   2.No 
7.4. Recent history of Infection   : 1.Yes   2.No 
7.5. Recent history of hospitalization  : 1.Yes   2.No 
7.6. History of Myocardial Infarction  : 1.Yes   2.No 
7.7. History of Kidney Disease   : 1.Yes   2.No 
7.8. History of thyroid disorders   : 1.Yes   2.No 
7.9. Any known co-existing morbidity : 1.Yes   2.No 
7.10. If yes, details     : 
7.11. History of Drug intake   :  
 
 
 
 
 
 
Master chart for controls 
 
S.No 
Age 
in 
years 
Gender 
BMI 
Kg/m
2 
Fasting 
blood 
sugar 
mg/dL 
Serum 
Total 
Cholesterol 
mg/dL 
Serum 
triglyceride 
levels 
mg/dL 
Serum HDL 
Cholesterol 
mg/dL 
Serum LDL 
Cholesterol 
mg/dL 
Plasma 
MPO 
activity 
U/L 
1 34 F 17.10 104 232 156 46 168 176.15 
2 51 M 18.56 107 144 71 35 94 37.37 
3 39 F 19.57 85 156 86 61 123 16.01 
4 46 M 19.71 91 200 152 87 128 362.98 
5 44 F 20.06 94 240 140 41 170 53.38 
6 54 M 20.34 88 185 146 33 131 160.14 
7 50 M 21.14 97 136 127 65 154 339.14 
8 52 M 21.46 114 192 147 35 127 181.49 
9 43 F 22.1 83 102 123 39 134 85.408 
10 38 F 23 95 135 105 46 108 69.394 
11 58 M 23.05 86 165 312 31 86 144.13 
12 49 M 23.83 95 200 127 28 112 459.07 
13 42 F 23.94 99 229 91 59 146 379.00 
14 32 F 24 103 150 154 48 85 96.084 
15 65 M 24.03 109 216 91 60 137 85.41 
16 40 F 24.34 93 241 82 61 164 106.76 
17 48 M 24.39 97 176 128 42 123 106.76 
18 48 M 25.00 115 113 97 18 67 368.32 
19 44 F 25.40 115 140 60 29 91 53.38 
20 48 M 25.59 97 212 109 38 124 272.24 
21 36 F 25.71 107 227 212 40 160 48.04 
22 56 M 25.77 91 144 45 41 93 96.08 
23 40 F 26.1 89 125 100 54 120 48.042 
24 41 F 26.13 87 134 108 20 93 101.42 
25 33 F 26.17 97 185 108 39 133 381.84 
26 54 M 26.22 96 170 121 43 106 69.39 
27 61 M 26.37 88 183 147 42 121 160.14 
28 52 M 26.42 120 206 99 38 146 213.52 
29 33 F 26.73 106 224 131 50 150 69.39 
30 45 M 26.91 94 169 63 55 97 106.76 
31 55 M 27.34 90 164 205 32 103 324.13 
32 50 M 27.51 102 205 120 45 139 48.04 
33 57 M 27.59 90 172 192 44 104 373.66 
34 44 F 27.72 81 252 138 77 151 37.37 
S.No 
Age 
in 
years 
Gender 
BMI 
Kg/m
2 
Fasting 
blood 
sugar 
mg/dL 
Serum 
Total 
Cholesterol 
mg/dL 
Serum 
triglyceride 
levels 
mg/dL 
Serum HDL 
Cholesterol 
mg/dL 
Serum LDL 
Cholesterol 
mg/dL 
Plasma 
MPO 
activity 
U/L 
35 65 M 27.78 95 223 213 44 161 517.79 
36 61 M 27.83 92 178 54 63 103 101.42 
37 50 M 28.60 102 234 160 40 125 213.52 
38 52 M 29 90 132 132 55 98 102.42 
39 60 M 29.09 96 195 80 45 136 37.37 
40 34 F 30.12 87 155 180 33 145 365.83 
41 44 F 30.13 103 200 273 45 113 416.36 
42 40 F 30.86 100 173 95 45 118 416.36 
43 42 F 31.10 85 212 168 31 155 145.58 
44 63 M 31.20 98 174 127 48 107 53.38 
45 45 F 32.4 87 142 98 60 115 53.38 
46 57 M 33.32 115 162 41 42 106 373.66 
47 54 M 33.67 102 230 109 56 152 213.52 
48 52 M 34.25 96 200 92 33 148 266.90 
49 57 M 35.84 103 195 169 45 124 96.08 
50 48 M 36.11 84 181 135 44 115 416.36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Master chart for cases 
S.No Age Gender 
BMI 
kg/m
2 
Fasting 
blood 
sugar 
mg/dL 
Serum 
Total 
Cholesterol 
mg/dL 
Serum 
triglceride 
levels 
mg/dL 
Serum HDL 
cholesterol 
mg/dL 
Serum LDL 
cholesterol 
mg/dL 
Plasma 
MPO 
activity 
U/L 
HbA1c 
Duration 
of DM 
1 45 M 18.67 158 137 85 39 92 138.79 7.28 5 
2 57 F 19.38 236 260 136 52 188 288.25 12.65 20 
3 48 M 19.56 198 187 113 59 121 160.14 9.80 1 
4 51 F 19.95 313 198 85 50 144 245.55 11.25 13 
5 48 F 20.55 131 160 107 32 109 298.93 8.19 5 
6 60 M 21.34 133 253 296 41 175 352.35 6.16 10 
7 55 M 22.14 185 210 176 45 145 321.52 9.52 14 
8 49 F 22.15 200 228 95 51 154 362.98 11.63 8 
9 69 M 22.31 168 192 120 53 122 218.86 6.55 7 
10 54 F 22.52 250 166 342 35 92 165.48 9.66 5 
11 65 F 22.66 184 207 112 41 149 585.25 6.50 17 
12 59 M 23.05 233 200 163 35 135 133.45 6.93 1 
13 40 M 23.07 216 155 205 32 70 368.32 6.90 2 
14 45 M 23.26 345 137 162 39 80 234.87 6.68 3 
15 53 M 24.06 195 191 182 31 140 165.48 13.69 10 
16 79 M 24.22 136 140 200 45 100 197.51 6.65 15 
17 69 M 24.39 195 144 62 73 99 133.45 7.59 25 
18 40 F 24.59 225 180 150 50 172 293.59 9.20 1 
19 58 F 24.88 184 197 138 46 144 138.79 5.90 10 
20 54 M 25.71 168 198 203 31 147 128.11 11.83 3 
21 44 M 25.82 154 198 192 31 126 122.77 8.40 2 
22 37 M 25.86 165 130 118 37 81 133.45 6.94 8 
23 43 M 26.30 135 220 109 37 79 170.82 6.10 2 
24 55 M 27.06 145 244 572 31 130 1110.30 11.90 1 
25 54 F 27.18 123 190 64 55 111 160.14 7.80 15 
26 42 M 27.25 345 182 143 44 127 352.31 9.70 1 
27 50 F 27.41 142 164 94 54 105 544.45 6.40 5 
28 64 M 27.58 123 176 72 54 115 341.63 7.08 3 
29 72 F 27.97 225 187 123 45 122 176.15 7.88 21 
30 40 F 28.13 362 180 200 65 85 128.11 6.80 3 
31 58 F 28.69 346 195 219 41 127 245.55 6.82 3 
32 68 M 29.00 235 198 159 47 113 160.14 7.40 5 
33 32 F 29.00 154 250 185 30 120 520.45 8.45 4 
34 44 M 29.37 320 180 197 35 125 544.48 6.51 3 
35 32 M 29.41 154 269 120 37 189 128.11 6.50 1 
36 31 M 29.43 140 165 46 37 90 1035.57 8.41 4 
S.No Age Gender 
BMI 
kg/m
2 
Fasting 
blood 
sugar 
mg/dL 
Serum 
Total 
Cholesterol 
mg/dL 
Serum 
triglceride 
levels 
mg/dL 
Serum HDL 
cholesterol 
mg/dL 
Serum LDL 
cholesterol 
mg/dL 
Plasma 
MPO 
activity 
U/L 
HbA1c 
Duration 
of DM 
37 40 F 29.55 154 200 172 29 76 325.62 6.90 1 
38 50 M 29.64 256 178 110 52 185 165.48 6.39 8 
39 43 F 30.48 123 180 170 36 100 402.25 6.50 1 
40 52 M 30.49 348 189 291 40 111 261.56 6.20 3 
41 55 F 30.82 154 271 400 50 139 1225.65 11.10 6 
42 65 M 32.03 126 150 181 33 94 176.15 6.56 10 
43 38 M 32.28 186 148 191 39 93 314.94 6.10 2 
44 63 M 32.47 143 150 128 49 88 752.66 7.10 9 
45 38 M 32.83 150 154 191 46 83 165.48 6.46 1 
46 63 M 33.15 119 165 83 40 106 208.18 7.50 6 
47 48 F 34.02 205 198 154 55 154 340.62 6.45 13 
48 36 M 35.13 210 221 129 42 147 224.20 6.60 2 
49 45 M 35.38 354 175 146 48 135 265.32 8.24 11 
50 65 M 41.01 365 238 117 31 86 224.20 6.32 25 
 
 
 
 
 
 
 
 
 
 
 
 
